

THE PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE

England & Wales · Charity number 1118192

Details

Other names	PAPAA
Status	Registered
Legal form	Charitable company
Company number	06074887
Registered	2007-03-02
Register	View on the Charity Commission register

Contact

Address	3 Horseshoe Business Park Lye Lane Bricket Wood St Albans Hertfordshire AL2 3TA
Phone	01923672873
Email	info@papaa.org
Website	www.papaa.org

Activities

Objects: (A) THE RELIEF OF SICKNESS AND THE PRESERVATION OF HEALTH AMONG PEOPLE INCLUDING (BUT NOT LIMITED TO) THOSE SUFFERING FROM PSORIASIS, PSORIATIC ARTHROPATHY AND OTHER RELATED OR SIMILAR CONDITIONS;(B) TO PROMOTE AND PROTECT THE PHYSICAL AND MENTAL HEALTH OF SUFFERERS OF PSORIASIS, PSORIATIC ARTHROPATHY AND OTHER RELATED OR SIMILAR CONDITIONS THROUGH THE PROVISION OF FINANCIAL ASSISTANCE, SUPPORT, EDUCATION AND PRACTICAL ADVICE TO SUFFERERS AND THEIR FAMILIES AND THEIR CARERS; (C) TO ADVANCE THE EDUCATION OF THE MEDICAL PROFESSION, THE NURSING PROFESSION, THE MEDIA AND THE GENERAL PUBLIC IN ALL AREAS RELATING TO PSORIASIS, PSORIATIC ARTHROPATHY AND OTHER RELATED OR SIMILAR CONDITIONS; AND(D) TO PROMOTE OR ASSIST IN THE PROMOTION OF RESEARCH INTO THE CAUSES, PREVENTION, ALLEVIATION AND THE MANAGEMENT OF PSORIASIS, PSORIATIC ARTHROPATHY AND OTHER RELATED OR SIMILAR CONDITIONS, AND TO DISSEMINATE THE USEFUL RESULTS OF SUCH RESEARCH FOR THE PUBLIC BENEFIT.

Activities: The charity is working towards being the principal independent source of information and support to those affected by psoriasis and psoriatic arthritis. To reach this goal the charity maintains and continues to develop material and other useful programmes, which are designed to help people manage their psoriasis and psoriatic arthritis more effectively.

Classification

- **How:** Makes Grants To Individuals, Makes Grants To Organisations, Provides Human Resources, Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research, Acts As An Umbrella Or Resource Body
- **What:** General Charitable Purposes, Education/training, The Advancement Of Health Or Saving Of Lives, Disability
- **Who:** Children/young People, Elderly/old People, People With Disabilities, The General Public/mankind

Geography

- **Area of benefit:** NOT DEFINED IN PRACTICE NATIONAL
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-04-05	£30,948	£275,431	-	-
2024-04-05	£27,982	£278,492	-	-
2023-04-05	£96,405	£277,498	-	-
2022-04-05	£30,689	£259,565	-	-
2021-04-05	£31,179	£289,842	-	-

Trustees

Name	Role	Appointed
Paul Heinrich Sigismund von der Heyde	Chair	2017-03-09
CHARLES CAIRNS AULD		
Eugene Gerard Hayes		2022-03-01
JENNIFER PEEL		

THE PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE

England & Wales - Charity number 1118192

Accounts

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2025

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

CONTENTS

	Page
Reference and administrative details of the Charity, its Trustees and advisers	1
Trustees' report	2 - 9
Independent examiner's report	10 - 11
Statement of financial activities	12
Balance sheet	13 - 14
Notes to the financial statements	15 - 29

The following pages do not form part of the statutory financial statements:

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 5 APRIL 2025**

Trustees P H S Von Der Heyde, Chairman
 J M Peel, Trustee
 C C Auld, Trustee
 E G Hayes, Treasurer

**Company registered
number** 06074887

**Charity registered
number** 1118192

Registered office 30 Orange Street
 London
 WC2H 7HF

Accountants Calder & Co
 Chartered Accountants
 30 Orange Street
 London
 WC2H 7HF

Bankers Santander Business Banking
 PO Box 10102
 21 Prescott Street
 London
 E1 8TN

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**TRUSTEES' REPORT
FOR THE YEAR ENDED 5 APRIL 2025**

The Trustees present their annual report together with the financial statements of the Charity for the year 6 April 2024 to 5 April 2025.

The Trustees confirm that the Annual report and financial statements of the charitable company comply with the current statutory requirements, the requirements of the charitable company's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019).

Objectives and activities

a. Objectives and activities

- (a) The relief of sickness and the preservation of health among people including (but not limited to) those suffering from psoriasis, psoriatic arthropathy and other related or similar conditions;
- (b) To promote and protect the physical and mental health of sufferers of psoriasis, psoriatic arthropathy and other related or similar conditions through the provision of financial assistance, support, education and practical advice to sufferers and their families and their carers;
- (c) To advance the education of the medical profession, the nursing profession, the media and the general public in all areas relating to psoriasis, psoriatic arthropathy and other related or similar conditions; and
- (d) To promote or assist in the promotion of research into the causes, prevention, alleviation and the management of psoriasis, psoriatic arthropathy and other related or similar conditions, and to disseminate the useful results of such research for the public benefit.

The policies adopted in furtherance of these objects are:

- (1) To continue to provide support and advice to those affected either directly or indirectly by psoriasis and or psoriatic arthritis.
- (2) To actively educate the wider public about the conditions of psoriasis and psoriatic arthritis, by responding to direct contact with the charity and proactively contributing to media and public debates.
- (3) To continue developing, updating and providing free educational information in the form of leaflets, pamphlets, other printed material and a comprehensive website.
- (4) To investigate what areas of research are being undertaken and where the trustees feel it is appropriate, they will make grants available. Grants are made at the discretion of the trustees and in accordance with the objects of the charity.

There have been no changes to the objects or policies during the year.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2025

Achievements and performance

a. Review of activities

The trustees, as previously reported, have a clear strategy to continue to establish the charity as a global leader on patient-led support of people affected by psoriatic disease.

The priority areas of work include:

- Raising the knowledge of the conditions at primary care.
- Identifying unmet needs.
- Acting as a bridge for patients to navigate the NHS pathways.
- Signposting and providing educational support.
- Developing research funding.
- Developing support for parents of children with the disease.
- Expanding across all the popular modern media platforms.

To develop these aims, the charity engaged in a number of activities that would either expand the work or lead towards implementation in the future.

The following continue to be identified as areas to develop:

- Seek sponsorship/ grants.
- Develop applications to grant-giving trusts to support specific projects.
- Increase the charity profile for support at sponsored events.
- Use social media more.
- Develop further digital marketing.
- Advertise.
- Awareness campaigns.
- Micro training; transfer the written word into interactive training programmes.

Progress overview

This financial period has once again been shaped by broader global and national challenges. For charities like PAPAA, demand from our community continues to grow as people living with psoriasis and psoriatic arthritis encounter increasingly complex barriers to care. Changes in government policy, ongoing pressures related to the cost-of-living crisis, and persistent inequalities in healthcare access have compounded the daily challenges faced by many of those we support.

We have seen a notable increase in requests for guidance on navigating changing benefits systems, managing drug supply shortages, and addressing delays in face-to-face NHS appointments. At the same time, inflationary pressures have reduced disposable income for many donors, affecting charitable giving. Despite this, demand for our services, particularly in healthcare, has surged as the NHS continues to face intense strain. PAPAA has worked to bridge these gaps, with growing engagement from healthcare professionals in our education and patient support resources, and rising interest in our trusted patient information. Our materials are increasingly being referenced by the media to highlight lived experience and raise awareness of psoriatic disease.

The broader voluntary sector has also felt the impact of cuts in government support, reduced grants, and diminishing statutory contracts, leading to a search for new and sustainable sources of funding. International partnerships remain difficult, with Brexit-related economic changes still affecting collaboration and access to some opportunities.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2025

Achievements and performance (continued)

Amid these pressures, PAPAA has invested in building resilience through digital development. Trustees have anticipated the need for stronger digital infrastructure and have prioritised cost-effective innovation, including the use of Artificial Intelligence to enhance reach and efficiency. These changes allow the charity to keep overheads lean while maximising impact for our beneficiaries. Looking forward, PAPAA is also exploring further ways to contribute to the diagnosis and management of psoriatic disease, ensuring that we continue to adapt and grow in line with the evolving needs of the community we serve.

Key activities

The challenges facing the sector have shaped much of PAPAA's work this year and emphasised the importance of maintaining a sustainable organisation with secure income streams to support our mission. Building on commitments made in the previous annual report, several initiatives have been successfully implemented to improve engagement and fundraising. These include the introduction of a prominent donate button on every page of our website, making it easier for supporters to give directly, anonymously, or in recognition of events, with Gift Aid applied where possible to maximise contributions. Donation pages have been refreshed with new imagery, links to wider opportunities for involvement, and navigation widgets that improve user experience, while the Fundraising Regulator logo reinforces our commitment to best practice. Although some channels have closed, eBay for Charity and PayPal Giving continue to generate income, and interest in promotional items like PAPAA's journal and awareness wristbands remains steady.

As a leading source of trusted information on psoriatic disease, PAPAA continues to prioritise the sharing of high-quality, evidence-based resources. Our website has grown into one of the most comprehensive psoriatic disease platforms in the UK, with thousands of free-to-access items and resources. Website membership has now passed the 10,000 mark and gives access to PAPAA's expansive free-to-access knowledge bank.

An updated professional order form has seen strong growth and requests from our range of 26 printed patient information leaflets. Updates of material continue, based on a range of criteria to meet individual needs. Lay patient input, along with medical approval of content, remains an integral part of the standard we apply to information delivery.

Our printed Skin 'n' Bones Connection Journal is still distributed to those who require that format, but access digitally is being promoted widely to provide the broadest reach of this dedicated publication. Two other digital publications are also circulated to a dedicated list, our PAPAA News update and PsoPscience, the latter produced by Dr David Ashton as an easy read reflection of recent and interesting advances in psoriatic disease research. Social media continues to be used to promote our work and also as an enabler of requests for individuals to engage in research activities.

PAPAA's role in advocacy and representation has once again remained strong, with patient voices brought into decision-making through submissions to regulatory bodies including NICE, SMC, AWMSG, and MHRA.

Support for research, education, and training continues to be a central activity. Since its founding, PAPAA has invested close to three-quarters of a million pounds in research and training to improve the understanding and treatment of psoriatic disease, and we have provided subsidised access to Psoriasis in Practice CPD training for healthcare professionals. Anonymised peer support remains a valued service for individuals seeking connection and validation of their experiences. Together, these initiatives further our commitment to advancing knowledge and improving care pathways.

Membership of the International Federation of Psoriasis Associations (IFPA) was completed, and PAPAA has now established itself as the global psoriasis patient organisation for the UK within IFPA.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2025

Achievements and performance (continued)

To amplify visibility and extend outreach, we continue to make strategic use of the Google Ads Grant, worth \$120,000 annually in in-kind advertising, with plans to expand fundraising campaigns through this channel. The appointment of an external organisation to manage the grant has seen increases in page traffic and wider exposure of the charity's work. Analysis of activity has initiated a potential global opportunity to increase income.

Strategic ambitions

PAPAA's plans for the upcoming year and beyond focus on strengthening its impact and supporting the diverse, evolving needs of those affected by psoriatic disease:

- Elevating visibility and understanding of psoriatic disease and reinforcing PAPAA's role as a reliable, ethical charity.
- Expanding and diversifying educational resources for both patients and professionals, ensuring content is evidence-based, up-to-date, and accessible.
- Maintaining rigorous review and regular updates of website content, emphasising accuracy, clarity, and reliability for users.
- Investing in professional development by broadening training and CPD opportunities for healthcare providers involved in psoriatic care.
- Innovating in fundraising to build resilient income streams, supporting sustainability and the ability to fund new initiatives.
- Continuing to fund high-impact research that informs best practice and advances care for people with psoriatic disease.
- Deepening engagement with policymakers and regulators to ensure patient experience shapes policy, treatment access, and NHS service improvement.

Research priorities

PAPAA's Trustees continue to focus support on research activities that are likely to improve outcomes and understanding of psoriatic disease:

- Short-term observational studies to capture real-world outcomes of treatments and interventions.
- Feasibility and pilot studies exploring innovative or emerging approaches to care.
- Systematic reviews to synthesise and translate current evidence for both clinical and policy audiences.
- Small-scale epidemiological surveys to document prevalence, unmet needs, and the broader impact of psoriatic disease in the UK.
- Research on psoriatic disease in children and young people, with a view to improving understanding of diagnostic, treatment, and long-term support challenges.

PAPAA's focus remains firmly on advancing understanding and improving care for individuals affected by psoriatic disease through targeted, high-impact research initiatives. As an NIHR Non-commercial Research Designated Network (RDN) Partner, PAPAA's inclusion in the NIHR Clinical Research Network (CRN) Portfolio provides vital NHS support and access to the network's extensive infrastructure. This affiliation enhances PAPAA's ability to facilitate and contribute to research that is directly relevant to psoriatic disease, ensuring better recruitment of study participants, broader NHS integration, and efficient translation of findings into clinical practice.

Looking ahead, PAPAA will continue leveraging this strategic partnership to maximise the impact of its funded studies, reinforcing the charity's credibility and influence in shaping clinical guidelines and improving patient care across the UK.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2025

Achievements and performance (continued)

Ethical fundraising

PAPAA is dedicated to maintaining the highest ethical standards in fundraising. It remains a member of the Fundraising Regulator, maintaining transparency and clear communication on how fundraising is managed. This commitment ensures all fundraising activities uphold openness, honesty, and accountability.

The charity actively engages with stakeholders across the psoriasis and psoriatic arthritis community while carefully considering ethical implications related to funding sources. PAPAA guards its integrity by avoiding funding that could compromise its independence or public trust, thus keeping the focus squarely on supporting patients without undue commercial influence. The role of commercial partners and sponsors is being explored, with a keen view to abide by all ethical approaches and guidelines, such as those produced by the ABPI.

External activities

Collaboration with other organisations is integral to PAPAA's advocacy efforts. The charity works closely with professional bodies such as the British Association of Dermatologists and the British Society for Rheumatology to ensure patient perspectives inform clinical care, research, and policy development. These partnerships strengthen PAPAA's capacity to influence national healthcare standards and raise awareness of psoriatic disease among medical professionals.

PAPAA staff are responsive to requests from partner organisations, sharing insights drawn from patient experiences to help shape healthcare practices and policies that better meet patient needs. This solidifies PAPAA's role as a key advocate within the psoriatic disease community.

Data and evidence gathering

PAPAA employs a robust data collection strategy through electronic and open-access surveys, building a nuanced understanding of patient needs and experiences. This original data informs engagement with regulatory bodies such as NICE, SMC, and AWMSG during medicine appraisals, providing critical patient perspectives that complement clinical data and garner recognition from patient engagement teams.

The charity also proactively addresses concerns raised by patients to the MHRA regarding misleading advertising and counterfeit products. PAPAA's involvement in regulatory safety campaigns extends its influence and public benefit beyond psoriatic disease, championing patient safety and ethical industry practices.

Unmet needs

Through website features like Your Views and Share Your Story and ongoing analysis of user interactions, PAPAA continuously identifies unmet patient needs. These insights guide the development of new content and services, ensuring relevance and responsiveness to the evolving psoriatic disease community.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2025

Achievements and performance (continued)

Core work

PAPAA sustains essential day-to-day activities, including:

- Responding promptly to enquiries from patients, healthcare professionals, and the public.
- Monitoring website performance to maintain resource accessibility and relevance.
- Engaging users for feedback and community building.
- Exploring varied fundraising strategies to secure sustainability.
- Raising public awareness and promoting the charity's work.
- Participating in external events to network and raise profile.
- Active social media engagement to broaden reach and share education.
- Horizon scanning to stay abreast of research and treatment developments.
- Producing and reviewing publications for accuracy and utility.

Public benefit

PAPAA is committed to enhancing understanding of psoriatic disease and raising awareness through scientifically grounded, realistic support for all affected, from childhood through older age. The charity offers comprehensive resources across disease stages, prioritising evidence-based, patient-centred care.

Privacy and security

PAPAA operates an open-access, confidential information line using a peer-to-peer approach, providing empathetic support and guidance on navigating NHS services.

The charity strictly adheres to GDPR requirements, safeguarding all personal data with care and reinforcing trust among the communities it supports.

Conclusion

PAPAA has continued to consolidate its position as a leading charity supporting people affected by psoriatic disease. Despite ongoing external challenges, the organisation has maintained steady progress across its strategic priorities, including raising awareness, expanding educational resources, and enhancing patient support services.

The charity's proactive approach to digital transformation and fundraising has strengthened sustainability while ensuring engagement remains high among beneficiaries and healthcare professionals. Through active partnerships, targeted research funding, and robust advocacy, PAPAA has effectively contributed to advancing knowledge and improving care pathways across the UK.

Looking forward, the charity remains committed to refining its activities, increasing its reach, and deepening its impact, always guided by the needs of the people it serves. This steady advancement reaffirms PAPAA's essential role as a trusted resource and advocate in the field of psoriasis and psoriatic arthritis.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2025

Achievements and performance (continued)

Financial review

a. Reserves policy

In line with the guidance set out by the Charities Commission the Trustees have developed the following reserves policy to inform donors, funders and other stakeholders on how funds are being used to support the charity's aims and objectives.

The charity has previously used funds to generate income and also drawn on those funds to support its activities. A low risk balanced approach has been used to achieve this. The fund is now reducing and the Trustees are actively developing activities to generate new streams of income, whilst mindful of the need to use existing funds wisely, until such activities are able to support the work that is needed to support the charity's constituent group.

The cost of running the charity's activities is estimated to be approximately £300,000 per annum. Given that the charity provides its services and support free of charge, with only a small cost to cover the subscription to receive the journal via the post, reliance on the reserve is vital in the current climate to support activities.

Voluntary income through donations, regular gifts and legacies is a small part of the charity's income, therefore until new and regular income streams have been developed it is anticipated that further reliance on the reserve will be vital to maintain the current activities and the development of new much needed initiatives.

The current funds held by the charity at the end of the financial year are £528,075. Prudent management will continue in order to generate income, both to support daily activities with some provision to release funds to support the research activities and provide small grants to researchers working in the areas of ongoing interest to the Trustees. The allocation for research is anticipated to be around £60,000 per annum, dependent on applications being of a high standard and likely to provide meaningful results that add scientific value.

This policy is regularly monitored and reviewed for effectiveness in the light of the changing funding and financial climate and other risks by the Board of Trustees. It is adjusted accordingly as plans, opportunities and income streams emerge.

b. Designated funds

The trustees have decided that a designated fund should be allocated to grants for research. The charity operates an open application small research grant programme, with a maximum award per application of £10,000.

The size of the fund allocation is £60,000 per financial year, which reflects the current and anticipated level of applications based on funded projects within the portfolio and that of rejected applications in the current financial year.

It is anticipated that the fund will be spent within each financial year, if not the funds will be carried forward to create a rolling offer, or used for support, which the trustees proactively identify as meeting with the aims and objectives of the charity. Awards will only be made based on extensive and thorough vetting of the applications.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2025

Structure, governance and management

a. Constitution

The Charity is a charitable company limited by guarantee and was incorporated on 30 January 2007. The company took over the assets, liabilities and activities of the Psoriasis Support Trust, an unincorporated charity, on 6 April 2007 and of the Psoriatic Arthropathy Alliance charitable company limited by guarantee on 3 April 2009 as agreed by the trustees of both charities.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

P.H.S. Von Der Heyde (Chairman)
J. M. Peel
C. C. Auld
E.G. Hayes (Treasurer)

Approved by order of the members of the board of Trustees on 27 October 2025 and signed on their behalf by:

Paul von der Heyde

.....
P H S Von Der Heyde

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 5 APRIL 2025**

Independent examiner's report to the Trustees of Psoriasis and Psoriatic Arthritis Alliance ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 5 April 2025.

This report is made solely to the charity's trustees, as a body, in accordance with section 145 of the Charities Act 2011. My work has been undertaken so that I might state to the charity's trustees those matters I am required to state to them in this report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for my work, for this report, or for the opinions I have formed.

Responsibilities and basis of report

As the Trustees of the Charity (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

An independent examination does not involve gathering all the evidence that would be required in an audit and consequently does not cover all the matters that an auditor considers in giving their opinion on the financial statements. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide. Consequently I express no opinion as to whether the financial statements present a 'true and fair' view and my report is limited to those specific matters set out in the independent examiner's statement.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Charity as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

INDEPENDENT EXAMINER'S REPORT (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2025

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed: 

Dated: 27 October 2025

A Koupland

ACA

Calder & Co
Chartered Accountants
30 Orange Street
London
WC2H 7HF

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 5 APRIL 2025**

	Note	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Income from:				
Donations and legacies	2	13,417	13,417	8,513
Investments	3	17,531	17,531	19,469
Total income		30,948	30,948	27,982
Expenditure on:				
Raising funds	4	5,363	5,363	7,136
Charitable activities	5	270,068	270,068	271,356
Total expenditure		275,431	275,431	278,492
Net expenditure before net gains on investments		(244,483)	(244,483)	(250,510)
Net gains on investments	10	9,341	9,341	29,090
Net movement in funds		(235,142)	(235,142)	(221,420)
Reconciliation of funds:				
Total funds brought forward		763,217	763,217	984,637
Net movement in funds		(235,142)	(235,142)	(221,420)
Total funds carried forward		528,075	528,075	763,217

The Statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 15 to 29 form part of these financial statements.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)
REGISTERED NUMBER: 06074887

BALANCE SHEET
AS AT 5 APRIL 2025

	Note	2025 £	2024 £
Fixed assets			
Intangible assets	14	21,651	27,064
Tangible assets	15	2,104	2,806
Investments	16	454,774	673,069
		<u>478,529</u>	<u>702,939</u>
Current assets			
Debtors	17	2,600	3,481
Cash at bank and in hand		56,748	68,928
		<u>59,348</u>	<u>72,409</u>
Current liabilities			
Creditors: amounts falling due within one year	18	(9,802)	(12,131)
		<u>49,546</u>	<u>60,278</u>
Net current assets			
		<u>528,075</u>	<u>763,217</u>
Total net assets		<u><u>528,075</u></u>	<u><u>763,217</u></u>
Charity funds			
Restricted funds	19	-	-
Unrestricted funds	19	528,075	763,217
		<u>528,075</u>	<u>763,217</u>
Total funds		<u><u>528,075</u></u>	<u><u>763,217</u></u>

The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)
REGISTERED NUMBER: 06074887

BALANCE SHEET (CONTINUED)
AS AT 5 APRIL 2025

The financial statements were approved and authorised for issue by the Trustees on 27 October 2025 and signed on their behalf by:

Paul von der Heyde

.....
P H S Von Der Heyde

The notes on pages 15 to 29 form part of these financial statements.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2025**

1. Accounting policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Psoriasis and Psoriatic Arthritis Alliance meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The accounts present information about the company as an individual undertaking and not about its group. The company and its subsidiary undertaking comprise a small-sized group. The company has therefore taken advantage of the exemptions provided by section 398 of the Companies Act 2006 not to prepare group accounts.

1.2 Company status

The charity is a company limited by guarantee and has no share capital. Its registered office is 30 Orange Street, London WC2H 7HF. The members of the company are the Trustees named on page 1. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

The financial statements are prepared in sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £.

1.3 Going concern

The trustees have a reasonable expectation that the charity has adequate resources to continue in operation for the foreseeable future and are confident that the charity can continue as a going concern for a period of at least 12 months from the date of approval of these financial statements.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2025

1. Accounting policies (continued)

1.4 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

The recognition of income from legacies is dependent on establishing entitlement, the probability of receipt and the ability to estimate with sufficient accuracy the amount receivable. Evidence of entitlement to a legacy exists when the Charity has sufficient evidence that a gift has been left to them (through knowledge of the existence of a valid will and the death of the benefactor) and the executor is satisfied that the property in question will not be required to satisfy claims in the estate. Receipt of a legacy must be recognised when it is probable that it will be received and the fair value of the amount receivable, which will generally be the expected cash amount to be distributed to the Charity, can be reliably measured.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

Dividends are recognised once the dividend has been declared and notification has been received by our investment advisor of the investment portfolio.

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

Support costs are those costs incurred directly in support of expenditure on the objects of the company and include project management carried out at Headquarters.

Governance costs are those incurred in connection with administration of the company and compliance with constitutional and statutory requirements.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Charitable activities and Governance costs are costs incurred on the company's operations, including support costs and costs relating to the governance of the company apportioned to charitable activities.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2025**

1. Accounting policies (continued)

1.6 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

1.7 Intangible assets and amortisation

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Amortisation is provided on intangible assets at rates calculated to write off the cost of each asset, less their estimate residual value, over its expected useful lives.

Amortisation is provided on the following basis:

Website costs	-	20 % reducing balance
---------------	---	-----------------------

1.8 Tangible fixed assets and depreciation

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Plant and machinery	-	25%
Fixtures and fittings	-	25%

1.9 Fixed asset investments

Fixed asset Investments consists of listed investments and shares in a subsidiary undertaking.

Listed investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised In net income/(expenditure) for the year. Transaction costs are expensed as incurred.

The investment includes the charity's holding in its subsidiary trading company and is shown at cost.

A subsidiary is an entity controlled by the Charity. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2025**

1. Accounting policies (continued)

1.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.12 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of financial activities as a finance cost.

1.13 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.14 Pensions

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

1.15 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2025**

1. Accounting policies (continued)

1.16 Critical accounting estimates and areas of judgment

In the application of the Charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The Trustees do not consider there to be judgements or estimates that would be considered to be critical to the financial statements.

2. Income from donations and legacies

	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Donations	13,417	13,417	8,513

3. Investment income

	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Income from listed investments	14,778	14,778	16,043
Interest receivable	2,753	2,753	3,426
Total 2025	17,531	17,531	19,469

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2025**

4. Investment management costs

	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Investment management	5,363	5,363	7,136

5. Analysis of expenditure on charitable activities

Summary by fund type

	Unrestricted funds 2025 £	Total 2025 £	Total 2024 £
Support costs (see note 6)	224,327	224,327	216,219
Grant funding of activities (see note 7)	2,446	2,446	13,500
Direct costs (see note 8)	36,156	36,156	33,720
Governance costs (see note 9)	7,139	7,139	7,917
Total 2025	270,068	270,068	271,356

6. Support costs

	2025 £	2024 £
Staff Costs (see note 12)	171,132	162,979
Depreciation	6,115	7,694
Rent and rates	27,661	25,492
IT consultancy	11,820	11,433
Postage	4,621	4,579
Telephone and fax	894	448
Other expenses	580	476
Subscriptions	1,504	3,118
	224,327	216,219

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2025**

7. Grants payable

	2025 £	2024 £
DDM Health	2,446	13,500
	<u>2,446</u>	<u>13,500</u>

8. Direct costs

	2025 £	2024 £
Medical consultancy	22,200	21,600
Printing and stationery	13,956	12,120
	<u>36,156</u>	<u>33,720</u>

9. Governance costs

	2025 £	2024 £
Accountancy fees	5,524	4,044
Legal & professional	-	1,800
Insurance	1,615	2,073
	<u>7,139</u>	<u>7,917</u>

10. Net gains / (losses) on investments

	2025 £	2024 £
Revaluation of investments	(6,225)	(18,371)
Gain / (loss) on sale of investments	15,566	47,461
	<u>9,341</u>	<u>29,090</u>

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2025**

11. Independent examiner's remuneration

	2025 £	2024 £
Fees payable to the Charity's independent examiner for the independent examination of the Charity's annual accounts	<u>3,700</u>	<u>3,600</u>

12. Staff costs

	2025 £	2024 £
Wages and salaries	154,048	146,835
Social security costs	12,393	11,498
Contribution to defined contribution pension schemes	4,691	4,646
	<u>171,132</u>	<u>162,979</u>

The average number of persons employed by the Charity during the year was as follows:

	2025 No.	2024 No.
Administration	<u>3</u>	<u>3</u>

	2025	2024
In the band £60,001 - £70,000	1	2
In the band £70,001 - £80,000	1	-

13. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2024 - £NIL) and no Trustee expenses have been incurred (2024 - £NIL).

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2025**

14. Intangible assets

	Trademarks £
Cost	
At 6 April 2024	75,840
At 5 April 2025	75,840
Amortisation	
At 6 April 2024	48,776
Charge for the year	5,413
At 5 April 2025	54,189
Net book value	
At 5 April 2025	21,651
At 5 April 2024	27,064

15. Tangible fixed assets

	Plant and machinery £	Fixtures and fittings £	Total £
Cost or valuation			
At 6 April 2024	3,543	14,552	18,095
At 5 April 2025	3,543	14,552	18,095
Depreciation			
At 6 April 2024	3,491	11,798	15,289
Charge for the year	13	689	702
At 5 April 2025	3,504	12,487	15,991

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2025

15. Tangible fixed assets (continued)

	Plant and machinery £	Fixtures and fittings £	Total £
Net book value			
At 5 April 2025	<u>39</u>	<u>2,065</u>	<u>2,104</u>
<i>At 5 April 2024</i>	<u>52</u>	<u>2,754</u>	<u>2,806</u>

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2025**

16. Fixed asset investments

	Investments in subsidiary companies £	Listed investments £	Total £
Cost or valuation			
At 6 April 2024	1	673,068	673,069
Additions	-	19,529	19,529
Disposals	-	(231,599)	(231,599)
Revaluations	-	(6,225)	(6,225)
At 5 April 2025	<u>1</u>	<u>454,773</u>	<u>454,774</u>
Net book value			
At 5 April 2025	<u>1</u>	<u>454,773</u>	<u>454,774</u>
At 5 April 2024	<u>1</u>	<u>673,068</u>	<u>673,069</u>

Principal subsidiaries

The following were subsidiary undertakings of the company:

Name	Registered office	Principal activity	Holding
PAPAA Enterprises Limited	Calder & Co, 30 Orange Street, London, WC2H 7HF	Website Licence	100%

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2025**

17. Debtors

	2025 £	2024 £
Due within one year		
Other debtors	2,600	2,600
Prepayments and accrued income	-	881
	<u>2,600</u>	<u>3,481</u>

18. Creditors: Amounts falling due within one year

	2025 £	2024 £
Trade creditors	1,411	3,157
Other taxation and social security	4,301	4,984
Accruals and deferred income	4,090	3,990
	<u>9,802</u>	<u>12,131</u>

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2025**

19. Statement of funds

Statement of funds - current year

	Balance at 6 April 2024 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 5 April 2025 £
Designated funds						
Investment and research fund	1,039,600	-	-	(1,039,600)	-	-
Small research grant programmes	47,000	-	-	(47,000)	-	-
	<u>1,086,600</u>	<u>-</u>	<u>-</u>	<u>(1,086,600)</u>	<u>-</u>	<u>-</u>
General funds						
General Funds - all funds	(323,383)	30,948	(275,431)	1,086,600	9,341	528,075
Total Unrestricted funds	<u>763,217</u>	<u>30,948</u>	<u>(275,431)</u>	<u>-</u>	<u>9,341</u>	<u>528,075</u>

The investment and research fund represent sums set aside by the trustees for investments. To earn sufficient income to fund ongoing research in Psoriasis and Psoriatic Arthritis.

The trustees have decided that a designated fund should be allocated to grants for research. The charity operates an open application small research grant programme, with a maximum award per application of £10,000. The size of the fund allocation (47,000) reflects the current and anticipated level of applications based on funded projects within the portfolio and that of rejected applications in the current financial year.

It is anticipated that the fund will be spent within each financial year, but awards will only be made based on extensive and thorough vetting of the applications, unused funds will be carried over or used for support, which the trustees proactively identify as meeting with the aims and objectives of the charity.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2025**

19. Statement of funds (continued)

Statement of funds - prior year

	<i>Balance at 1 April 2023 £</i>	<i>Income £</i>	<i>Expenditure £</i>	<i>Gains/ (Losses) £</i>	<i>Balance at 5 April 2024 £</i>
Designated funds					
Investment and research fund	1,039,600	-	-	-	1,039,600
Small research grant programme	47,000	-	-	-	47,000
	<u>1,086,600</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>1,086,600</u>
General funds					
General Funds	(101,963)	27,982	(278,492)	29,090	(323,383)
	<u>(101,963)</u>	<u>27,982</u>	<u>(278,492)</u>	<u>29,090</u>	<u>(323,383)</u>
Total Unrestricted funds	<u>984,637</u>	<u>27,982</u>	<u>(278,492)</u>	<u>29,090</u>	<u>763,217</u>

20. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2025 £	Total funds 2025 £
Tangible fixed assets	2,104	2,104
Intangible fixed assets	21,651	21,651
Fixed asset investments	454,774	454,774
Current assets	59,348	59,348
Creditors due within one year	(9,802)	(9,802)
Total	<u>528,075</u>	<u>528,075</u>

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2025**

20. Analysis of net assets between funds (continued)

Analysis of net assets between funds - prior year

	Unrestricted funds 2024 £	Total funds 2024 £
Tangible fixed assets	2,806	2,806
Intangible fixed assets	27,064	27,064
Fixed asset investments	673,069	673,069
Current assets	72,409	72,409
Creditors due within one year	(12,131)	(12,131)
Total	<u>763,217</u>	<u>763,217</u>

21. Related party transactions

At the end of the year Psoriasis and Psoriatic Arthritis Alliance owed £1 (2024: £1) to PAPAA Enterprises Limited a wholly owned subsidiary.

THE PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE

England & Wales - Charity number 1118192

Accounts

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE

(A company limited by guarantee)
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2024

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

CONTENTS

	Page
Reference and administrative details of the charity, its trustees and advisers	1
Trustees' report	2 - 11
Independent examiner's report	12 - 13
Statement of financial activities	14
Balance sheet	15
Notes to the financial statements	16 - 28

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 5 APRIL 2024**

Trustees

P.H.S. Von Der Heyde, Chairman
J. M. Peel
C. C. Auld
E.G. Hayes, Treasurer

Company registered number

06074887

Charity registered number

1118192

Registered office

30 Orange Street, London, WC2H 7HF

Accountants

Calder & Co, 30 Orange Street, London, WC2H 7HF

Bankers

Santander Business Banking, PO Box 10102, 21 Prescott Street, London, E1 8TN

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT
FOR THE YEAR ENDED 5 APRIL 2024

The trustees present their report and financial statements for the year ended 5 April 2024.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity's trust deeds, the Charities Act 2011, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective from 1 January 2019).

Objectives and Activities

a. Objectives and activities

- (a) The relief of sickness and the preservation of health among people including (but not limited to) those suffering from psoriasis, psoriatic arthropathy and other related or similar conditions;
- (b) To promote and protect the physical and mental health of sufferers of psoriasis, psoriatic arthropathy and other related or similar conditions through the provision of financial assistance, support, education and practical advice to sufferers and their families and their carers;
- (c) To advance the education of the medical profession, the nursing profession, the media and the general public in all areas relating to psoriasis, psoriatic arthropathy and other related or similar conditions; and
- (d) To promote or assist in the promotion of research into the causes, prevention, alleviation and the management of psoriasis, psoriatic arthropathy and other related or similar conditions, and to disseminate the useful results of such research for the public benefit.

The policies adopted in furtherance of these objects are:

- (1) To continue to provide support and advice to those affected either directly or indirectly by psoriasis and or psoriatic arthritis.
- (2) To actively educate the wider public about the conditions of psoriasis and psoriatic arthritis, by responding to direct contact with the charity and proactively contributing to media and public debates.
- (3) To continue developing, updating and providing free educational information in the form of leaflets, pamphlets, other printed material and a comprehensive website.
- (4) To investigate what areas of research are being undertaken and where the trustees feel it is appropriate, they will make grants available. Grants are made at the discretion of the trustees and in accordance with the objects of the charity.

There have been no changes to the objects or policies during the year.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2024

Achievements and performance

a. Review of activities

- In previous annual reports, the trustees set-out a clear strategies to further establish the charity, by priority areas of work.

These include:

- Raise the knowledge of the conditions at primary care.
- Identify unmet needs.
- Acting as a bridge for patients to navigate the NHS pathways.
- Signposting and providing educational support.
- Developing research funding.
- Developing support of parents of children with the disease.
- Expanding across all the popular modern media platforms.

To develop these aims the charity engaged in a number of activities that would either expand the work or lead towards implementation in the future.

The following continue to be identified as areas to develop:

- Seek sponsorship/grants
- Develop applications to grant giving trusts to support specific projects.
- Increase the charity profile for support at sponsored events.
- Use social media more.
- Develop digital marketing.
- Advertise.
- Awareness campaigns.
- Micro training; transfer written word into interactive training programmes.

Progress overview

During this financial period, PAPAA, like many UK charities, has navigated an increasingly challenging environment shaped by a range of economic, social, and political factors. One of the most pressing challenges has been the ongoing cost-of-living crisis. Rising inflation and energy prices have impacted donors, reducing disposable income for charitable giving, while the demand for charitable services has surged, particularly in healthcare. With the NHS facing growing pressure to meet deadlines and obligations, PAPAA has seen an increase in demand for support, particularly as it fills gaps in patient care. This heightened demand is evident in the growing interest from healthcare professionals (HCPs) in PAPAA's patient support initiatives, including the organisation's expansive patient information resources. PAPAA has also gained increased visibility in media and news outlets, with many referencing the charity's materials to support stories based on lived experiences.

Simultaneously, the broader charity sector has been impacted by government funding cuts and policy changes, resulting in reduced grants and contracts for essential services, which has necessitated a search for alternative funding. Brexit-related economic shifts have further complicated matters, affecting funding opportunities and partnerships with European organisations.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2024

Despite these challenges, digital transformation has become both a necessity and an opportunity. PAPAA's trustees, foreseeing the need for digital infrastructure upgrades, have been proactive in embracing this transformation. The charity has begun to focus on utilising Artificial Intelligence (AI) and other cost-effective technologies, ensuring that PAPAA remains lean in expenditure, but highly effective in reaching and supporting those most in need. There are also ongoing explorations into expanding the charity's involvement in the diagnosis and management of psoriatic disease, reflecting PAPAA's commitment to evolving, in line with the needs of its beneficiaries.

Key activities

These challenges have been central to PAPAA's activities and underline the importance of sustaining the charity while ensuring viable income streams for future initiatives. The plans laid out in the previous annual report to support the charity's ambitions have been successfully implemented. This includes the introduction of a prominent 'donate' button on all pages of the website, allowing individuals to make direct donations, either anonymously, by name, or through a dedicated event page. Importantly, this feature also incorporates the option for Gift Aid to be applied to donations, maximising the impact of contributions.

To enhance engagement, donation pages have been improved with more imagery and links to other ways supporters can assist PAPAA. Additionally, 'widgets' have been included to simplify navigation, and the Fundraiser Regulator logo is now displayed, signifying PAPAA's ethical approach to fundraising. While some donation channels, such as Amazon Smile, have been discontinued, others, including eBay for Charity and PayPal Giving, have been successful, with donations continuing to flow in. There has also been steady interest in promotional items, such as PAPAA's magazine and awareness-raising wristbands.

A core part of PAPAA's positioning as the leading authority on psoriatic disease has been its active efforts to find and share relevant research and news on psoriasis and psoriatic arthritis. This ensures that PAPAA's information remains trustworthy, ethical, and evidence-based, reinforcing its reputation as a reliable resource.

In terms of digital marketing, PAPAA has expanded its efforts, making regular use of the Google Ads Grant, which provides \$120,000 annually in in-kind online advertising. The charity is also exploring further campaign developments to fully leverage this resource, particularly as a tool for fundraising.

PAPAA has continued to emphasise our commitment to public benefit and our status as a 'good cause,' promoting PAPAA's significant impact through the following initiatives:

- **Comprehensive online resource:** Our website is one of the most extensive psoriatic disease-specific resource in the UK, with nearly 10,000 free-to-access items and pages, providing vital information to both patients and healthcare professionals.
- **Printed educational material:** Over the last decade, we have distributed more than 200,000 plus free printed leaflets across 24 topics covering the core aspects of psoriasis and psoriatic arthritis.
- **Healthcare professional support:** More than 1,000 healthcare professionals have been provided with free patient support materials to aid their understanding and treatment of psoriatic diseases.
- **Pharmacy outreach:** We've supplied more than 3,500 UK pharmacies, helping them deliver free patient resources at the point of medicine delivery, enhancing patient education and care.
- **Biannual Journal:** Our journal, Skin 'n' Bones Connection, has been regularly distributed since 1993, providing up-to-date, trusted information to both patients and healthcare providers.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2024

- **Regulatory engagement:** PAPAA has represented patient views in UK regulatory bodies, such as NICE, SMC, AWMSG, and MHRA, ensuring that the lived experiences of those with psoriatic disease inform new drug appraisals and regulatory decisions.
- **Social media engagement:** We are actively engaged across the most popular social media platforms, with around 10,000 interactions, using these platforms to amplify patient voices and raise awareness.
- **Patient stories and surveys:** Through our engagement group and PAPAA surveys, we've gathered more than 5,000 comments, stories and suggestions based on the real-life experiences of those living with psoriatic disease.
- **Research and training funding:** We have invested nearly three-quarters of a million pounds into research and training initiatives in psoriatic disease, contributing to the advancement of knowledge and treatment.
- **Regular eNewsletter Updates:** More than 1,500 people receive regular updates via our eNewsletter, keeping our community informed of the latest developments, resources, and opportunities for engagement.
- **HCP Training:** We have provided continuing professional development (CPD) training through our Psoriasis in Practice programme, subsidising many healthcare professionals to access this essential training free of charge.
- **Peer support:** We offer anonymised peer support, providing a lifeline to those who are desperate for someone to listen to and validate their experiences.

Additionally, we have continued developing and promoting short informational videos, which are embedded in our main landing pages and shared across social media and YouTube. These videos have proven to be an effective way to reach a wider audience, providing accessible and engaging content that highlights PAPAA's mission and impact.

Further work and strategic ambitions

To build on our current impact and activities, PAPAA has developed several key ambitions to further its mission:

- **Raising visibility and profile:** We are committed to increasing awareness of both the charity and psoriatic disease, ensuring that more people understand the challenges faced by individuals living with these conditions and the support PAPAA offers.
- **Expanding information and support materials:** We will continue to enhance and diversify our range of educational materials, ensuring they are comprehensive, up-to-date, and accessible to patients and healthcare professionals alike.
- **Website maintenance and accuracy:** A priority for PAPAA is to regularly review and update our website to ensure that the information remains accurate, reliable, and aligned with the latest medical guidelines and patient needs.
- **Enhancing professional training:** We aim to improve and expand our training programs for healthcare professionals, providing them with the latest knowledge and skills to support individuals with psoriatic disease.
- **Developing fundraising strategies:** To ensure sustainability and growth, PAPAA will focus on developing new and innovative fundraising strategies to increase donations and diversify income streams.
- **Supporting research:** PAPAA remains committed to funding and supporting research initiatives that further our understanding of psoriatic disease, its treatment, and management.
- **External engagement:** We will continue to strengthen our engagement with external agencies, including regulators and policymakers, to advocate for improved care, treatment options, and patient outcomes.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2024

The trustees continue to focus on several key areas of interest to guide PAPAA's future research and support activities:

- **Short-term observational studies:** These studies are crucial for understanding the real-world impact of treatments and interventions in psoriatic disease over limited periods, offering valuable insights into patient outcomes and care approaches.
- **Funding feasibility and pilot studies:** The Trustees are particularly interested in supporting smaller, preliminary studies that test the viability of new research ideas or treatment approaches. These studies lay the groundwork for larger, more comprehensive research projects.
- **Systematic reviews:** Systematic reviews synthesize existing research and provide a clear, evidence-based understanding of specific issues in psoriasis and psoriatic arthritis, enabling better-informed decisions in both clinical and policy settings.
- **Small epidemiological surveys:** By funding smaller-scale surveys, PAPAA aims to gather essential data on the prevalence, distribution, and impacts of psoriatic disease within different populations. This information helps inform public health strategies and resource allocation.
- **Psoriasis and psoriatic arthritis in children:** Understanding how psoriatic disease affects children is a growing area of interest. The Trustees are keen to support research that explores the specific challenges faced by young people with psoriasis and psoriatic arthritis, including diagnosis, treatment, and long-term management.

These areas of focus reflect PAPAA's commitment to advancing understanding and improving the care of individuals affected by psoriatic disease through targeted, high-impact research initiatives.

PAPAA's inclusion in the **Network Portfolio** allows the charity to access vital NHS support through the **NIHR Clinical Research Network (CRN)** infrastructure. This affiliation provides an opportunity for PAPAA to contribute to and facilitate research that is directly relevant to psoriatic disease, benefiting from the resources and expertise of the NIHR CRN. By being part of this network, PAPAA can ensure that the research it supports is integrated within the NHS framework, enabling broader participation, more effective recruitment of study participants, and better implementation of findings into clinical practice.

Looking ahead, PAPAA will continue to support and engage with relevant research initiatives, leveraging this strategic partnership to maximize the impact of funded studies. This collaboration not only strengthens the credibility of the research PAPAA is involved in but also enhances its potential to influence clinical guidelines and patient care across the UK.

Ethical fundraising

PAPAA remains committed to maintaining the highest standards in its fundraising practices. As part of its efforts to increase awareness and develop fundraising strategies, the charity continues to be a member of the **Fundraising Regulator**, ensuring transparency and providing clear guidance to the public on how fundraising activities are managed. This membership underscores PAPAA's dedication to ethical fundraising, ensuring that the charity operates in a way that is open, honest, and accountable.

The charity actively listens to and engages with all stakeholders involved in the psoriasis and psoriatic arthritis field, fostering collaboration while remaining mindful of the ethical considerations surrounding fundraising. PAPAA is particularly cautious about how funding from certain sectors might be perceived by the public, ensuring that its integrity and independence are never compromised by overt commercial influence. This approach allows the charity to remain focused on its mission of supporting individuals affected by psoriatic disease, without being swayed by external pressures.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2024

By adhering to these principles, PAPAA reinforces its commitment to being a trusted and transparent organisation, ensuring that all donations are used effectively and ethically to advance its goals of patient support, research, and education.

External activities

Collaboration and engagement with other organisations and external agencies are key to PAPAA's advocacy efforts, as recognised by the charity's trustees. These partnerships play an essential role in representing and advocating for the interests of individuals affected by psoriasis and psoriatic arthritis.

PAPAA works closely with respected professional bodies such as the **British Association of Dermatologists** and the **British Society for Rheumatology**, ensuring that the patient perspective is included in discussions on clinical care, research, and policy development. These collaborations enhance the charity's ability to influence national healthcare standards and promote better understanding of psoriatic disease among medical professionals.

Additionally, PAPAA's staff remain responsive to requests from these and other organisations, providing insights and support drawn from the real-life experiences of patients. By sharing the lived experience of those managing psoriasis and psoriatic arthritis, PAPAA helps shape healthcare practices and policies to better meet the needs of patients, strengthening its role as a key advocate in the psoriatic disease community.

Data and evidence gathering

PAPAA maintains an ongoing process of data collection and analysis to better understand the needs of the individuals it supports. Through strategic distribution of electronic surveys and a standing open-access survey, PAPAA has built a comprehensive and nuanced view of the issues faced by people living with psoriasis and psoriatic arthritis. This original, often unpublished data provides invaluable insights that reflect the lived experiences of patients, shaping PAPAA's advocacy and engagement efforts.

The charity has successfully used this data to inform submissions to key regulatory bodies, including the **National Institute for Health and Care Excellence (NICE)**, the **Scottish Medicines Consortium (SMC)**, and the **All-Wales Medicines Strategy Group (AWMSG)**, during drug appraisals for new medicines. The inclusion of real-life patient experiences has proven to be highly valuable, offering a perspective that traditional clinical data cannot always capture. PAPAA has received positive feedback from these agencies, with formal appreciation from the **Patient and Public Engagement** teams for its meaningful contributions.

Responding to calls from medicine agencies is an essential aspect of PAPAA's representation role. In addition to contributing to drug appraisals, the charity has proactively engaged with the **Medicines and Healthcare Products Regulatory Agency (MHRA)**, raising concerns about misleading advertising, inappropriate product promotion, and the availability of fake or adulterated medicines related to psoriasis and psoriatic arthritis. This work is based on a combination of operational evaluations and direct feedback from individuals living with the condition.

PAPAA's close engagement with regulatory bodies has led to invitations to contribute to safety campaigns, extending the charity's influence and public benefit beyond psoriatic disease. By advocating for patient safety and integrity in product marketing, PAPAA helps protect the public from harmful practices, further reinforcing its commitment to ethical representation and patient advocacy.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2024

Unmet needs

PAPAA remains actively engaged with its constituent group to identify and address unmet needs, particularly through the Your Views and Share Your Story sections of the website. These platforms enable individuals to share their experiences, concerns, and suggestions, providing the charity with valuable insights into patient perspectives. Regular surveys have further highlighted key areas of importance to patients, helping PAPAA stay attuned to emerging themes and priorities within the psoriatic disease community.

In addition to direct interactions, PAPAA also conducts an ongoing analysis of website search terms and user activity. This helps to identify topics that require further exploration or support, allowing the charity to respond proactively to the needs of its community. These insights influence the creation of new content and resources, ensuring that PAPAA's offerings remain relevant, informative, and aligned with the evolving needs of those affected by psoriasis and psoriatic arthritis.

By continuously gathering data from various sources, PAPAA is better equipped to address unmet needs and expand its support activities, strengthening its role as a responsive and patient-centred organisation.

Core work

In addition to its forward-planning ambitions, PAPAA continues to carry out essential day-to-day activities that support individuals affected by psoriatic disease. These core activities include:

- **Responding to all enquiry routes:** The charity is committed to addressing inquiries from patients, healthcare professionals, and the public, ensuring that everyone has access to the information and support they need.
- **Maintaining and monitoring website activity:** PAPAA regularly reviews website performance and user engagement to ensure that resources remain accessible and relevant.
- **Proactively engaging with users:** Ongoing outreach efforts help PAPAA stay connected with its constituents, allowing for direct feedback and fostering a sense of community.
- **Seeking ways to raise funds:** The charity actively explores diverse fundraising strategies to ensure sustainability and support for its initiatives.
- **Raising awareness and promoting the charity:** PAPAA continues to engage in awareness campaigns to educate the public about psoriatic disease and the charity's work, expanding its reach and impact.
- **Engaging in external events:** Participation in relevant external events enhances networking opportunities and raises the charity's profile within the healthcare community.
- **Social media postings:** Active social media engagement allows PAPAA to connect with a broader audience, share updates, and promote educational content.
- **Horizon scanning of latest developments:** PAPAA keeps abreast of the latest developments in research and treatment related to psoriatic disease to inform its activities and initiatives.
- **Producing and monitoring publications:** The charity produces informative publications that are regularly monitored for accuracy and relevance, ensuring that they meet the needs of patients and healthcare providers alike.

By maintaining a strong focus on both public engagement and core activities, PAPAA is well-positioned to fulfil its mission of supporting individuals living with psoriasis and psoriatic arthritis while continuously adapting to their evolving needs.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2024

Public benefit

PAPAA is dedicated to enhancing understanding of psoriasis and psoriatic arthritis while raising awareness among a wider audience. This commitment is central to the charity's mission, as it strives to provide realistic, evidence-based support underpinned by scientific rigor. Meeting the needs of all individuals affected by these conditions, from cradle to grave, remains a priority for PAPAA. The charity recognizes the importance of offering comprehensive resources and support throughout the various stages of life and disease progression.

Privacy and security

PAPAA maintains a strong policy of open access to a confidential and anonymous helpline, ensuring that individuals feel safe and supported when seeking assistance. The helpline operates on a peer-to-peer approach, where staff listen empathetically and offer directional advice on maximising the services provided within the NHS framework. This supportive environment is often praised by service users, who find the approach particularly beneficial during challenging times, whether they are newly diagnosed or transitioning to a different phase of their health journey.

The ability to provide time, resources, and tailored signposting is highly valued by those who reach out for support. Many individuals return for follow-up calls, indicating the effectiveness of this ongoing engagement. PAPAA is deeply committed to safeguarding the well-being, privacy, and security of all information shared by those it engages with. The charity adheres to the principles set out in the General Data Protection Regulation (GDPR), ensuring that personal data is handled responsibly and with the utmost care.

Through its dedication to public benefit and the protection of personal information, PAPAA continues to foster trust and confidence among the communities it serves, ensuring that individuals affected by psoriasis and psoriatic arthritis receive the support they need in a safe and secure environment.

Conclusion

PAPAA's strategic initiatives and robust engagement efforts have significantly advanced its mission to support individuals living with psoriasis and psoriatic arthritis. Despite the challenging landscape posed by economic pressures, the charity has effectively navigated obstacles through innovative fundraising strategies, a commitment to digital transformation, and the expansion of educational resources. The positive feedback from healthcare professionals and patients' alike highlights PAPAA's vital role in bridging gaps in patient care and providing comprehensive support.

By fostering collaborations with external organisations and actively advocating for the interests of those affected by psoriatic disease, PAPAA continues to strengthen its influence within the healthcare community. The charity's dedication to addressing unmet needs, maintaining a high standard of privacy and security, and adhering to ethical fundraising practices underscores its commitment to transparency and integrity.

Looking ahead, PAPAA remains focused on enhancing its outreach, expanding its research funding, and continually adapting to the evolving needs of its beneficiaries. Through these efforts, the charity is well-positioned to make a lasting impact in the lives of individuals affected by psoriasis and psoriatic arthritis, ultimately contributing to a greater understanding and improved management of these conditions.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2024

Financial review

a. Reserves policy

In line with the guidance set out by the Charities Commission the Trustees have developed the following reserves policy to inform donors, funders and other stakeholders on how funds are being used to support the charity's aims and objectives.

The charity has previously used funds to generate income and also drawn on those funds to support its activities. A low risk balanced approach has been used to achieve this. The fund is now reducing and the Trustees are actively developing activities to generate new streams of income, whilst mindful of the need to use existing funds wisely, until such activities are able to support the work that is needed to support the charity's constituent group.

The cost of running the charity's activities is estimated to be approximately £300,000 per annum. Given that the charity provides its services and support free of charge, with only a small cost to cover the subscription to receive the journal via the post, reliance on the reserve is vital in the current climate to support activities.

Voluntary income through donations, regular gifts and legacies is a small part of the charity's income, therefore until new and regular income streams have been developed it is anticipated that further reliance on the reserve will be vital to maintain the current activities and the development of new much needed initiatives.

The current funds held by the charity at the end of the financial year are £763,217. Prudent management will continue in order to generate income, both to support daily activities with some provision to release funds to support the research activities and provide small grants to researchers working in the areas of ongoing interest to the Trustees. The allocation for research is anticipated to be around £60,000 per annum, dependent on applications being of a high standard and likely to provide meaningful results that add scientific value.

This policy is regularly monitored and reviewed for effectiveness in the light of the changing funding and financial climate and other risks by the Board of Trustees. It is adjusted accordingly as plans, opportunities and income streams emerge.

b. Designated funds

The trustees have decided that a designated fund should be allocated to grants for research. The charity operates an open application small research grant programme, with a maximum award per application of £10,000.

The size of the fund allocation is £60,000 per financial year, which reflects the current and anticipated level of applications based on funded projects within the portfolio and that of rejected applications in the current financial year.

It is anticipated that the fund will be spent within each financial year, if not the funds will be carried forward to create a rolling offer, or used for support, which the trustees proactively identify as meeting with the aims and objectives of the charity. Awards will only be made based on extensive and thorough vetting of the applications.

Structure, governance and management

a. Constitution

The Charity is a charitable company limited by guarantee and was incorporated on 30 January 2007. The company took over the assets, liabilities and activities of the Psoriasis Support Trust, an unincorporated charity,

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2024

on 6 April 2007 and of the Psoriatic Arthropathy Alliance charitable company limited by guarantee on 3 April 2009 as agreed by the trustees of both charities.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

P.H.S. Von Der Heyde (Chairman)
J. M. Peel
C. C. Auld
E.G. Hayes (Treasurer)

This report was approved by the Trustees, on 4 November 2024 and signed on their behalf by:

Paul von der Heyde

.....
P.H.S. Von Der Heyde

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 5 APRIL 2024**

Independent examiner's report to the Trustees of Psoriasis and Psoriatic Arthritis Alliance (the 'company')

I report to the trustees (who are also Directors for the purpose of company law) on my examination of the accounts of the company for the year ended 5 April 2024 which comprise the Statement of Financial Activities, the Balance Sheet and related notes.

This report is made solely to the charity's trustees, as a body, in accordance with section 145 of the Charities Act 2011. My work has been undertaken so that I might state to the charity's trustees those matters I am required to state to them in this report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for my work, for this report, or for the opinions I have formed.

Responsibilities and basis of report

As the Trustees of the company (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charitable company's financial statements carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

An independent examination does not involve gathering all the evidence that would be required in an audit and consequently does not cover all the matters that an auditor considers in giving their opinion on the financial statements. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide. Consequently I express no opinion as to whether the financial statements present a 'true and fair' view and my report is limited to those specific matters set out in the independent examiner's statement.

Independent examiner's statement


I have completed my examination. I can confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

INDEPENDENT EXAMINER'S REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2024

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed: 

Dated: 4 November 2024

A Koupland ACA

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**STATEMENT OF FINANCIAL ACTIVITIES INCORPORATING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 5 APRIL 2024**

	Note	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Income from:				
Donations and legacies	2	8,513	8,513	77,438
Investments	3	19,469	19,469	18,967
Total income		27,982	27,982	96,405
Expenditure on:				
Raising funds		7,136	7,136	8,443
Charitable activities		271,356	271,356	269,055
Total expenditure	4	278,492	278,492	277,498
Net expenditure before investment gains/(losses)		(250,510)	(250,510)	(181,093)
Net gains / (losses) on investments	10	29,090	29,090	(40,845)
Net expenditure before other recognised gains and losses		(221,420)	(221,420)	(221,938)
Net movement in funds		(221,420)	(221,420)	(221,938)
Reconciliation of funds:				
Total funds brought forward		984,637	984,637	1,206,575
Total funds carried forward		763,217	763,217	984,637

The notes on pages 16 to 28 form part of these financial statements.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)
REGISTERED NUMBER: 06074887

BALANCE SHEET
AS AT 5 APRIL 2024

	Note	£	2024 £	£	2023 £
Fixed assets					
Intangible assets	14		27,064		33,830
Tangible assets	15		2,806		3,734
Investments	16		673,069		855,520
			702,939		893,084
Current assets					
Debtors	17	3,481		3,481	
Cash at bank and in hand		68,928		99,348	
		72,409		102,829	
Creditors: amounts falling due within one year	18	(12,131)		(11,276)	
Net current assets			60,278		91,553
Net assets			763,217		984,637
Charity Funds					
Unrestricted funds	19		763,217		984,637
Total funds			763,217		984,637

The company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The Trustees consider that the company is entitled to exemption from the requirement to have an audit under the provisions of section 477 of the Companies Act 2006 ("the Act") and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Act.

The Trustees acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements were approved and authorised for issue by the Trustees on 4 November 2024 and signed on their behalf, by:

Paul von der Heyde

.....
P.H.S. Von Der Heyde

The notes on pages 16 to 28 form part of these financial statements.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2024

1. Accounting policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Psoriasis and Psoriatic Arthritis Alliance meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The accounts present information about the company as an individual undertaking and not about its group. The company and its subsidiary undertaking comprise a small-sized group. The company has therefore taken advantage of the exemptions provided by section 398 of the Companies Act 2006 not to prepare group accounts

1.2 Company status

The charity is a company limited by guarantee and has no share capital. Its registered office is 30 Orange Street, London WC2H 7HF. The members of the company are the Trustees named on page 1. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

The financial statements are prepared in sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £.

1.3 Going concern

The trustees have a reasonable expectation that the charity has adequate resources to continue in operation for the foreseeable future and are confident that the charity can continue as a going concern for a period of at least 12 months from the date of approval of these financial statements.

1.4 Income

All income is recognised once the company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

For legacies, entitlement is taken as the earlier of the date on which either: the company is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the company has been notified of the executor's intention to make a distribution. Where legacies have been notified to the company, or the company is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Dividends are recognised once the dividend has been declared and notification has been received by our investment advisor of the investment portfolio.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2024

1. Accounting policies (continued)

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

Support costs are those costs incurred directly in support of expenditure on the objects of the company and include project management carried out at Headquarters.

Governance costs are those incurred in connection with administration of the company and compliance with constitutional and statutory requirements.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Charitable activities and Governance costs are costs incurred on the company's operations, including support costs and costs relating to the governance of the company apportioned to charitable activities.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

1.6 Intangible fixed assets and amortisation

Intangible assets are initially recognised at cost and are subsequently measured at cost net of amortisation and any provision for impairment.

Amortisation is provided on intangible fixed assets at rates calculated to write off the cost of each asset, less their estimated residual value, over their expected useful lives on the following bases:

Website cost	- 20% reducing balance
--------------	------------------------

1.7 Tangible fixed assets and depreciation

A review for impairment of a fixed asset is carried out if events or changes in circumstances indicate that the carrying value of any fixed asset may not be recoverable. Shortfalls between the carrying value of fixed assets and their recoverable amounts are recognised as impairments. Impairment losses are recognised in the Statement of financial activities incorporating income and expenditure account.

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Plant and machinery	- 25% reducing balance
Fixtures and fittings	- 25% reducing balance

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2024**

1. Accounting policies (continued)

1.8 Fixed asset investments

Fixed asset Investments consists of listed investments and shares in a subsidiary undertaking.

Listed investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

The investment includes the charity's holding in its subsidiary trading company and is shown at cost.

A subsidiary is an entity controlled by the Charity. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.9 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the company; this is normally upon notification of the interest paid or payable by the Bank.

1.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.11 Cash at Bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.12 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

1.13 Financial instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.14 Pensions

The company operates a defined contribution pension scheme and the pension charge represents the amounts payable by the company to the fund in respect of the year.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2024

1. Accounting policies (continued)

1.15 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

1.16 Critical accounting estimates and areas of judgment

In the application of the Charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The Trustees do not consider there to be judgements or estimates that would be considered to be critical to the financial statements.

2. Income from donations and legacies

	Unrestricted funds 2024 £	Total funds 2024 £	<i>Total funds 2023 £</i>
Donations	8,513	8,513	77,438
<i>Total 2023</i>	<i>77,438</i>	<i>77,438</i>	

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2024**

3. Investment income

	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Income from listed investments	16,043	16,043	16,554
Interest receivable	3,426	3,426	2,413
	<u>19,469</u>	<u>19,469</u>	<u>18,967</u>
<i>Total 2023</i>	<u>18,967</u>	<u>18,967</u>	

4. Analysis of charitable expenditure

	Charitable expenditure 2024 £	Total 2024 £	Total 2023 £
Raising funds:			
Investment management (see note 5)	7,136	7,136	8,443
Subtotal raising funds	<u>7,136</u>	<u>7,136</u>	<u>8,443</u>
Charitable activities:			
Support costs (see note 8)	216,219	216,219	211,579
Direct costs (see note 6)	33,720	33,720	38,267
Grant funding of activities (see note 7)	13,500	13,500	-
Subtotal charitable activities	<u>263,439</u>	<u>263,439</u>	<u>249,846</u>
Expenditure on governance (see note 9)	<u>7,917</u>	<u>7,917</u>	<u>19,209</u>
	<u>278,492</u>	<u>278,492</u>	<u>277,498</u>
<i>Total 2023</i>	<u>277,498</u>	<u>277,498</u>	

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2024**

5. Raising funds

	Unrestricted funds 2024 £	Total funds 2024 £	<i>Total funds 2023 £</i>
Investment management	7,136	7,136	8,443
	<u>7,136</u>	<u>7,136</u>	<u>8,443</u>
<i>Total 2023</i>	<u>8,443</u>	<u>8,443</u>	

6. Direct costs

	Information and Support Services £	Total 2024 £	<i>Total 2023 £</i>
Medical consultancy	21,600	21,600	21,250
Printing and stationery	12,120	12,120	17,017
	<u>33,720</u>	<u>33,720</u>	<u>38,267</u>
<i>Total 2023</i>	<u>38,267</u>	<u>38,267</u>	

7. Grants payable

	Grants 2024 £	Total 2024 £	<i>Total 2023 £</i>
DDM Health	13,500	13,500	-
	<u>13,500</u>	<u>13,500</u>	<u>-</u>

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2024**

8. Support costs

	Information and Support Services £	Total 2024 £	Total 2023 £
Staff costs	162,979	162,979	157,494
Depreciation	7,694	7,694	9,762
Rent and rates	25,492	25,492	26,371
IT consultancy	11,433	11,433	11,506
Postage	4,579	4,579	3,599
Telephone and fax	448	448	463
Other expenses	476	476	913
Subscriptions	3,118	3,118	1,471
	<u>216,219</u>	<u>216,219</u>	<u>211,579</u>
<i>Total 2023</i>	<u>211,579</u>	<u>211,579</u>	

During the year ended 5 April 2024, the company incurred the following Governance costs:

9. Governance costs

	Unrestricted funds 2024 £	Total funds 2023 £
Accountancy fees	4,044	7,470
Legal and professional	1,800	9,916
Insurance	2,073	1,823
	<u>7,917</u>	<u>19,209</u>

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2024

10. Net gains / (losses) on investments

	2024 £	2023 £
Revaluation of investments	(18,371)	(51,407)
Gain / (loss) on sale of investments	47,461	10,562
Total	29,090	(40,845)

11. Average number of employees

The average number of persons employed by the company during the year was as follows:

	2024 No.	2023 No.
Administration	3	4

One employee received emoluments totalling £67,200 and a second employee received emoluments of £66,000. This includes national insurance and pension contributions. No other employees received emoluments exceeding £50,000.

12. Independent examiner

The Independent Examiner's remuneration amounts to an Independent Examination fee of £3,600 (2023 - £3,600).

13. Trustees

During the year no trustees (or any persons connected with them) received any remuneration or reimbursed expenses. (2023: £ nil)

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2024**

14. Intangible fixed assets

	Website Costs £
Cost	
At 6 April 2023 and 5 April 2024	75,840
Amortisation	
At 6 April 2023	42,010
Charge for the year	6,766
At 5 April 2024	48,776
Carrying amount	
At 5 April 2024	27,064
<i>At 5 April 2023</i>	33,830

15. Tangible fixed assets

	Plant and machinery £	Fixtures and fittings £	Total £
Cost			
At 6 April 2023 and 5 April 2024	3,543	14,552	18,095
Depreciation			
At 6 April 2023	3,480	10,881	14,361
Charge for the year	11	917	928
At 5 April 2024	3,491	11,798	15,289
Net book value			
At 5 April 2024	52	2,754	2,806
<i>At 5 April 2023</i>	63	3,671	3,734

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2024**

16. Fixed asset investments

	Listed securities £	Sub total carried forward £
Market value		
At 6 April 2023	855,519	855,519
Additions	78,591	78,591
Disposals	(242,671)	(242,671)
Valuation changes	(18,371)	(18,371)
	<u>673,068</u>	<u>673,068</u>
At 5 April 2024	<u>673,068</u>	<u>673,068</u>
	Sub total brought forward £	investment in subsidiary £
Market value		Total £
At 6 April 2023	855,519	1
Additions	78,591	-
Disposals	(242,671)	-
Valuation changes	(18,371)	-
	<u>673,068</u>	<u>1</u>
At 5 April 2024	<u>673,068</u>	<u>1</u>

Subsidiary undertakings

The following were subsidiary undertakings of the company:

Name	Holding	2024 £	2023 £
PAPAA Enterprises Limited	100%	1	1

Name	Business	Registered office
PAPAA Enterprises Limited	Website Licence	Calder & Co 30 Orange Street London WC2H 7HF

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2024**

17. Debtors

	2024 £	2023 £
Other debtors	2,600	2,600
Prepayments and accrued income	881	881
	<u>3,481</u>	<u>3,481</u>

18. Creditors: Amounts falling due within one year

	2024 £	2023 £
Trade creditors	3,156	3,053
Other taxation and social security	4,984	4,382
Amount owed to subsidiary undertaking	1	1
Accruals and deferred income	3,990	3,840
	<u>12,131</u>	<u>11,276</u>

19. Statement of funds

Statement of funds - current year

	Balance at 6 April 2023 £	Income £	Expenditure £	Gains/ (Losses) £	Balance at 5 April 2024 £
Designated funds					
Investment and research fund	1,039,600	-	-	-	1,039,600
Small research grant programme	47,000	-	-	-	47,000
	<u>1,086,600</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>1,086,600</u>
General funds					
General Funds	(101,963)	27,982	(278,492)	29,090	(323,383)
Total Unrestricted funds	<u>984,637</u>	<u>27,982</u>	<u>(278,492)</u>	<u>29,090</u>	<u>763,217</u>
Total of funds	<u>984,637</u>	<u>27,982</u>	<u>(278,492)</u>	<u>29,090</u>	<u>763,217</u>

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2024**

19. Statement of funds (continued)

The investment and research fund represent sums set aside by the trustees for investments. To earn sufficient Income to fund on going research in Psoriasis and Psoriatic Arthritis.

The trustees have decided that a designated fund should be allocated to grants for research. The charity operates an open application small research grant programme, with a maximum award per application of £10,000. The size of the fund allocation (£47,000) reflects the current and anticipated level of applications based on funded projects within the portfolio and that of rejected applications in the current financial year.

It is anticipated that the fund will be spent within each financial year, but awards will only be made based on extensive and thorough vetting of the applications, unused funds will be carried over or used for support, which the trustees proactively identify as meeting with the aims and objectives of the charity.

Statement of funds - prior year

	<i>Balance at 6 April 2022</i> £	<i>Income</i> £	<i>Expenditure</i> £	<i>Gains/ (Losses)</i> £	<i>Balance at 5 April 2023</i> £
Designated funds					
Investment and research fund	1,039,600	-	-	-	1,039,600
Small research grant programme	47,000	-	-	-	47,000
	<u>1,086,600</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>1,086,600</u>
General funds					
General Funds	119,975	96,405	(277,498)	(40,845)	(101,963)
Total Unrestricted funds	<u>1,206,575</u>	<u>96,405</u>	<u>(277,498)</u>	<u>(40,845)</u>	<u>984,637</u>
Total of funds	<u>1,206,575</u>	<u>96,405</u>	<u>(277,498)</u>	<u>(40,845)</u>	<u>984,637</u>

20. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2024 £
Intangible fixed assets	27,064
Tangible fixed assets	2,806
Fixed asset investments	673,069
Current assets	72,409
Creditors due within one year	(12,131)
	<u>763,217</u>

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2024

20. Analysis of net assets between funds (continued)

Analysis of net assets between funds - prior year

	<i>Unrestricted funds 2023 £</i>
Intangible fixed assets	33,830
Tangible fixed assets	3,734
Fixed asset investments	855,520
Current assets	102,829
Creditors due within one year	(11,276)
	984,637

21. Related party transactions

Remuneration of key management personnel	2024	2023
	£	£
Aggregate compensation	67,200	64,400

At the end of the year Psoriasis and Psoriatic Arthritis Alliance owed £1 (2023: £1) to PAPAA Enterprises Limited a wholly owned subsidiary.

THE PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE

England & Wales - Charity number 1118192

Accounts

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE

(A company limited by guarantee)

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 5 APRIL 2023

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

CONTENTS

	Page
Reference and administrative details of the charity, its trustees and advisers	1
Trustees' report	2 - 9
Independent examiner's report	10 - 11
Statement of financial activities	12
Balance sheet	13
Notes to the financial statements	14 - 26

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 5 APRIL 2023**

Trustees

P.H.S. Von Der Heyde, Chairman
J. M. Peel
C. C. Auld
E.G. Hayes, Treasurer

Company registered number

06074887

Charity registered number

1118192

Registered office

30 Orange Street, London, WC2H 7HF

Accountants

Calder & Co, 30 Orange Street, London, WC2H 7HF

Bankers

Santander Business Banking, PO Box 10102, 21 Prescott Street, London, E1 8TN

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT
FOR THE YEAR ENDED 5 APRIL 2023

The trustees present their report and financial statements for the year ended 5 April 2023.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity's trust deeds, the Charities Act 2011, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective from 1 January 2019).

Objectives and Activities

a. Objectives and activities

- (a) The relief of sickness and the preservation of health among people including (but not limited to) those suffering from psoriasis, psoriatic arthropathy and other related or similar conditions;
- (b) To promote and protect the physical and mental health of sufferers of psoriasis, psoriatic arthropathy and other related or similar conditions through the provision of financial assistance, support, education and practical advice to sufferers and their families and their carers;
- (c) To advance the education of the medical profession, the nursing profession, the media and the general public in all areas relating to psoriasis, psoriatic arthropathy and other related or similar conditions; and
- (d) To promote or assist in the promotion of research into the causes, prevention, alleviation and the management of psoriasis, psoriatic arthropathy and other related or similar conditions, and to disseminate the useful results of such research for the public benefit.

The policies adopted in furtherance of these objects are:

- (1) To continue to provide support and advice to those affected either directly or indirectly by psoriasis and or psoriatic arthritis.
- (2) To actively educate the wider public about the conditions of psoriasis and psoriatic arthritis, by responding to direct contact with the charity and proactively contributing to media and public debates.
- (3) To continue developing, updating and providing free educational information in the form of leaflets, pamphlets, other printed material and a comprehensive website.
- (4) To investigate what areas of research are being undertaken and where the trustees feel it is appropriate, they will make grants available. Grants are made at the discretion of the trustees and in accordance with the objects of the charity.

There have been no changes to the objects or policies during the year.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2023

Achievements and performance

a. Review of activities

In the previous annual report, the trustees set-out a clear strategy to further establish the charity, by priority areas of work.

These are as follows:

- Raise the knowledge of the conditions at primary care.
- Identify unmet needs.
- Act as a bridge for patients to navigate the NHS pathways.
- Signpost and provide educational support.
- Develop research funding.
- Develop support of parents of children with the disease.
- Expand across all the popular modern media platforms.

To develop these aims the charity engaged in a number of activities that would either expand the work or lead towards implementation in the future. The following had been identified as areas to develop:

- Seek sponsorship/grants to provide FREE access for nurses to PAPAA online training.
- Develop applications to grant giving trusts to support specific projects.
- Increase the charity profile for support at sponsored events.
- Use social media more.
- Develop digital marketing.
- Advertise.
- Awareness campaigns.
- Micro training; transfer written word into interactive training programmes.

Progress

The announcement of the lifting of COVID restrictions in February 2022 and the UK Government's introduction of the "living with COVID " plan, provided a chance to resume activities that had been heavily restricted during the pandemic. The difficulties still remained for this financial year, particularly for the generation of income. The onset of the issues in Ukraine, impacted on global costs and a general continuation of the anxiety that had previously been experienced by people during the pandemic, which affected all aspects of society. Therefore, the resumption and progress of plans remained slower than would have been envisaged.

The lessons learned during the restrictions, such as working from home and the familiarity of video conferences has improved the ability to attend important meetings, which previously would have been prohibitive, too costly or time consuming to attend, have now become a normal part of the working environment. A hybrid working pattern has now been established and provides a useful opportunity for staff to have a flexible approach and work easily, using cloud and virtual office collaboration products.

With the return of out-patient clinics and regular routine patient monitoring, distribution continued to return to previous levels, with printed material and posters being in demand once again. The regular review and updates of material was able to resume too, with reaccreditation under the PIF-TICK trusted information creator scheme being attained again. New material has also been developed along with updating of older material.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2023

Key activities

The resumption of the trustees' plans was continued, with most activities progressing. Prior to the COVID pandemic, plans were developed to facilitate the process of receiving donations. This included an obvious 'donate' button on all pages on the website, allowing people to make direct donations. These can be anonymous, named or as a dedicated page for an event with donations being paid directly to the charity. It also allows GiftAid to be added to donations

In the donation pages the presentations have been enhanced with images and further links to other ways to support PAPAA. The inclusion of 'widgets' to make click through easier has also been added, as has the Fundraiser Regulator logo, which provides details of our ethical approach to fundraising. Some donation activities such as Amazon Smile, were discontinued, but eBay for charity as a nominated good cause, donations via PayPal Giving, were received and there was continued interest in promotional awareness items, such as our magazine and wristbands etc.

We continued to emphasise our 'good cause' and public benefit status, by promoting our impact, which includes the following:

- The most comprehensive psoriatic disease specific website in the UK, with nearly 10,000 free to access items and pages
- A range of 23 printed leaflets on the core aspects of psoriasis and psoriatic arthritis, with more than 200,000 distributed free in the last 10-years.
- More than 1,000 health care professionals provided with free patient support material.
- Supported 3,500 UK pharmacies to provide free patient resource at the point of medicine delivery.
- Biannual journal called Skin 'n' Bones Connection regularly distributed since 1993 to patients and a wide range of healthcare providers.
- Engaged and represented patient views with UK regulators including NICE, SMC, AWMSG and the MHRA to provide input into new drug appraisals and regulatory affairs.
- Actively engaged across the most popular social media applications, with around 10,000 interactions.
- Gathered real stories via our engagement group and PAPAA surveys with more than 5,000 individual views and suggestions from lived-experience of psoriatic disease.
- Around three-quarters of a million pounds provided to support research and training initiatives in psoriatic disease.
- Regular updates provided via an eNewsletter to more than 1,400 people.
- Trained multidisciplinary healthcare professional via our CPD accredited Psoriasis in Practice programme, with many subsidised to access the training at no cost.
- Provided anonymised access to peer-support to those often desperate for someone to listen and hear their voice.

We have continued to develop short promotional videos, which are imbedded in the main landing pages posted across our social media pages and YouTube channel.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2023

A campaign slogan was developed to provide a simple message strapline to convey what PAPAA does under the words 'CARE - CAUSE - CURE'

- Care = Support and education – information, website, training programmes/events.
- Cause = Research – funding relevant aligned projects.
- Cure = Facilitating the conversation to meet peoples' needs.

Further work to support that activity, has been developed with the ambition include:

- Raising visibility and profile of the charity and disease.
- Further develop information and support material.
- Review and continue to keep website accurate.
- Improve and expand professional training.
- Develop fundraising strategies to increase donations.
- Provide research funding and support.
- Continue external engagement with relevant agencies.

Differential and collaborative activities

Collaboration is seen as a good way to reduce duplication, share ideas and combine efforts with other likeminded organisations. The charity continued to be a partner in the Connect Immune Research initiative, which is a collective of 11 organisations, the other 10 are, type 1 diabetes charity JDRF, MS Society, Versus Arthritis, the British Society for Immunology, Alopecia UK, Coeliac UK, Bowel Research UK, British Thyroid Foundation, Royal Free Charity and myaware. The continued intention is to learn how immune disorders are linked, to help influence research and innovative approaches to collaboration.

Psoriasis in Practice

The charity's online course, was once again updated and fully reviewed by Julie Van Onselen and reaccredited by the Royal College of Nursing until 6th June 2023, further reaccreditation has taken place with course now approved until 3rd July 2024.

In the participant feedback we received the following comments:

"I did enjoy the course, I have gained substantial useful information about psoriasis, thank you for your support during my learning"

"This is an excellent educational package that represents exemplary educational practices and encourages proactive engagement and learning."

"I have a more in-depth knowledge of the conditions covered and can apply it to my patients"

"I see many patients with psoriasis, this course helped me understand the condition better and improved my approach to caring for patients with psoriasis."

Research funding

The ambition to support well-run research projects under a small grants scheme continued. The previously funded projects were completed, following the suspension due to relocation of research staff due to COVID restrictions. Although, applications for research grants were received during the year, following detailed review, the trustees felt unable to support the applicants. Follow-on studies were approved for the next financial year, to look at wider comorbidities linked to psoriatic disease and a study that would see if, reduction in weight could help control psoriasis disease progression, through monitoring health, via an APP.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2023

The following continue to be the main areas of interest to the trustees:

- Short term observational studies.
- Funding of feasibility and pilot studies.
- Systematic reviews.
- Small epidemiological surveys.
- Psoriasis and psoriatic arthritis in children.

PAPAA continues to hold partner status with the National Institute for Health Research (NIHR), which allows eligible research projects to be included in the NIHR Clinical Research Network Portfolio and therefore able to access NHS support via the NIHR Clinical Research Network infrastructure. Further support of relevant research will continue.

Ethical fundraising

As part of awareness and fundraising development, the charity continues to be a member of the Fundraising Regulator, to provide transparency and a clear guide to the public about the way in which we will manage our fundraising activities. The charity cordially listens and engages with all those interested and working within the psoriasis and psoriatic arthritis arena; and continues to be mindful of how funding from certain sectors is perceived by the public, to avoid compromising the organisation's integrity and independence from overtly commercial influence.

External activities

Collaboration and involvement with other organisations and external agencies are seen by the charity trustees as an important part of the advocacy and representation of the organisation's constituent group. This includes work with the British Association of Dermatologists, and The British Society for Rheumatology. Staff continue to respond to requests for support and to provide the patient lived-experience of psoriasis and psoriatic arthritis.

Data and evidence gathering

An ongoing process of data and evidence gathering and analysis of user issues, along with strategic distribution of electronic surveys and a standing open access PAPAA survey, have built a broad view of the needs of the constituent group the charity represents.

The use of this original generally unpublished data aided the submission of the patient's 'lived experience' to the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All-Wales Medicines Strategy Group (AWMSG) to drug appraisals for new medicines; the process has proven to be very valuable and provide a real-life perspective. Positive feedback was received following submissions, with the charity's approach being formally appreciated by the Patient and Public Engagement teams of the respective agencies.

Responding to calls from medicine agencies is seen as an important PAPAA representation role. This has also included proactive engagement by raising alarms and alerts to the Medicines Health Regulator Authority (MHRA), regarding misleading advertising, inappropriate promotion of psoriasis and psoriatic arthritis products, and where fake or adulterated medicine is being made available. This work is jointly from evaluation of the area of operation and through direct contact from people with the condition. This close engagement has also seen invitations to contribute to safety campaigns that provided a wider value beyond our area of work, by also providing a public benefit.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2023

Unmet needs

We have continued to engage with our constituent group particularly via our 'your views' and 'share your story' sections of our website. Regular surveys have allowed us to identify areas and themes that are important to patients. Analysis of website search terms and activity along with direct interaction with people has identified a number of topics where exploration is required. This work continues to influence the production of new content and support activities.

Public and patient engagement

This has become an important part of our work and aligns with growing expectation that charities need to demonstrate how their work is influenced by those they serve. PAPAA is continuing to engage with patients and the public in order to help our patient-centred approach to provide support based on need. We have an active user group that provides input and support.

Core work

Apart from the forward planning ambitions of the charity, there still remains core day-to-day activities that continue to be carried out in support of people affected by psoriasis and psoriatic arthritis, these include:

- Responding to all enquiry routes.
- Maintaining and monitoring website activity.
- Proactively engaging with users.
- Seeking ways to raise funds.
- Actively raising awareness and promoting the charity.
- Engaging in external events.
- Social media postings.
- Horizon scanning of latest developments.
- Producing and monitoring publications.

Public benefit

Supporting people to understand psoriasis and psoriatic arthritis and raise awareness to a wider audience has continued to be part of the work of the charity. Providing realistic support, that is backed by evidence and scientific rigour is key to that support. The role of meeting all those affected needs from cradle to grave also continues to be of the utmost importance.

Privacy and security

A policy of open access to a confidential and anonymous helpline, has also been maintained. The support that is given generally follows a peer-to-peer approach of listening, showing empathy and then directional advice of how to get the most out of the services provided within the NHS framework. This work, although, often intense and in-depth, is often praised by service users as a useful and effective approach to supporting them in what can be a very difficult period, whether newly diagnosed or entering a different phase of life or disease stage. The ability to provide time, resource and signposting is also valued, with returning calls to seek further support often taking place. The charity maintains the highest level of awareness towards the well-being, privacy and security of the information provided by those it engages with, as set out in the General Data Protection Regulation (GDPR).

Conclusion

In what continued to be a difficult year for society, the charity was able to continue to provide a full range of support and services, not only to its constituent group, but also to the wider public. The continuing global events impacted on income generation and other activities saw a lower than expected income stream, whilst more demand for support continued. The charity was able to use its reserves to continue to provide the support and

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2023

services to all those who needed them. It is clear that COVID-19 has continued to have a detrimental effect on the global economy, as have other world events. The work of the charitable sector, where income generation may not be able to match the growing needs of those who need their support, remains a challenge. The trustees and those involved with the charity, will aim to provide all that is possible to continue to help those affected by psoriasis and psoriatic arthritis, particularly during these uncertain and challenging times.

Financial review

a. Reserves policy

In line with the guidance set out by the Charities Commission the Trustees have developed the following reserves policy to inform donors, funders and other stakeholders on how funds are being used to support the charity's aims and objectives.

The charity has previously used funds to generate income and also drawn on those funds to support its activities. A low risk balanced approach has been used to achieve this. The fund is now reducing and the Trustees are actively developing activities to generate new streams of income, whilst mindful of the need to use existing funds wisely, until such activities are able to support the work that is needed to support the charity's constituent group.

The cost of running the charity's activities is estimated to be approximately £300,000 per annum. Given that the charity provides its services and support free of charge, with only a small cost to cover the subscription to receive the journal via the post, reliance on the reserve is vital in the current climate to support activities.

Voluntary income through donations, regular gifts and legacies is a small part of the charity's income, therefore until new and regular income streams have been developed it is anticipated that further reliance on the reserve will be vital to maintain the current activities and the development of new much needed initiatives.

The current funds held by the charity at the end of the financial year are £984,637. Prudent management will continue in order to generate income, both to support daily activities with some provision to release funds to support the research activities and provide small grants to researchers working in the areas of ongoing interest to the Trustees. The allocation for research is anticipated to be around £60,000 per annum, dependent on applications being of a high standard and likely to provide meaningful results that add scientific value.

This policy is regularly monitored and reviewed for effectiveness in the light of the changing funding and financial climate and other risks by the Board of Trustees. It is adjusted accordingly as plans, opportunities and income streams emerge.

b. Designated funds

The trustees have decided that a designated fund should be allocated to grants for research. The charity operates an open application small research grant programme, with a maximum award per application of £10,000.

The size of the fund allocation is £60,000 per financial year, which reflects the current and anticipated level of applications based on funded projects within the portfolio and that of rejected applications in the current financial year.

It is anticipated that the fund will be spent within each financial year, if not the funds will be carried forward to create a rolling offer, or used for support, which the trustees proactively identify as meeting with the aims and objectives of the charity. Awards will only be made based on extensive and thorough vetting of the applications.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2023

Structure, governance and management


a. Constitution

The Charity is a charitable company limited by guarantee and was incorporated on 30 January 2007. The company took over the assets, liabilities and activities of the Psoriasis Support Trust, an unincorporated charity, on 6 April 2007 and of the Psoriatic Arthropathy Alliance charitable company limited by guarantee on 3 April 2009 as agreed by the trustees of both charities.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

P.H.S. Von Der Heyde (Chairman)
J. M. Peel
C. C. Auld
E.G. Hayes (Treasurer)

This report was approved by the Trustees, on 16 October 2023 and signed on their behalf by:



.....
P.H.S. Von Der Heyde

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 5 APRIL 2023**

Independent examiner's report to the Trustees of Psoriasis and Psoriatic Arthritis Alliance (the 'company')

I report to the trustees (who are also Directors for the purpose of company law) on my examination of the accounts of the company for the year ended 5 April 2023 which comprise the Statement of Financial Activities, the Balance Sheet and related notes.

This report is made solely to the charity's trustees, as a body, in accordance with section 145 of the Charities Act 2011. My work has been undertaken so that I might state to the charity's trustees those matters I am required to state to them in this report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for my work, for this report, or for the opinions I have formed.

Responsibilities and basis of report

As the Trustees of the company (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charitable company's financial statements carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

An independent examination does not involve gathering all the evidence that would be required in an audit and consequently does not cover all the matters that an auditor considers in giving their opinion on the financial statements. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide. Consequently I express no opinion as to whether the financial statements present a 'true and fair' view and my report is limited to those specific matters set out in the independent examiner's statement.

Independent examiner's statement

I have completed my examination. I can confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

INDEPENDENT EXAMINER'S REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2023

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Signed:

Dated: 16 October 2023

A Koupland ACA

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**STATEMENT OF FINANCIAL ACTIVITIES INCORPORATING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 5 APRIL 2023**

	Note	Unrestricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
Income from:				
Donations and legacies	2	77,438	77,438	13,226
Investments	3	18,967	18,967	17,463
Total income		96,405	96,405	30,689
Expenditure on:				
Raising funds		8,443	8,443	10,556
Charitable activities		269,055	269,055	249,009
Total expenditure	4	277,498	277,498	259,565
Net expenditure before investment gains/(losses)		(181,093)	(181,093)	(228,876)
Net gains / (losses) on investments	10	(40,845)	(40,845)	48,851
Net expenditure before other recognised gains and losses		(221,938)	(221,938)	(180,025)
Net movement in funds		(221,938)	(221,938)	(180,025)
Reconciliation of funds:				
Total funds brought forward		1,206,575	1,206,575	1,386,600
Total funds carried forward		984,637	984,637	1,206,575

The notes on pages 14 to 26 form part of these financial statements.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE

(A company limited by guarantee)

REGISTERED NUMBER: 06074887

BALANCE SHEET
AS AT 5 APRIL 2023

	Note	£	2023 £	£	2022 £
Fixed assets					
Intangible assets	14		33,830		42,287
Tangible assets	15		3,734		5,039
Investments	16		855,520		1,072,697
			<u>893,084</u>		<u>1,120,023</u>
Current assets					
Debtors	17	3,481		3,481	
Cash at bank and in hand		99,348		90,884	
		<u>102,829</u>		<u>94,365</u>	
Creditors: amounts falling due within one year	18	(11,276)		(7,813)	
Net current assets			<u>91,553</u>		<u>86,552</u>
Net assets			<u>984,637</u>		<u>1,206,575</u>
Charity Funds					
Unrestricted funds	19		984,637		1,206,575
Total funds			<u>984,637</u>		<u>1,206,575</u>

The company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The Trustees consider that the company is entitled to exemption from the requirement to have an audit under the provisions of section 477 of the Companies Act 2006 ("the Act") and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Act.

The Trustees acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements were approved and authorised for issue by the Trustees on 16 October 2023 and signed on their behalf, by:



.....
P.H.S. Von Der Heyde

The notes on pages 14 to 26 form part of these financial statements.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2023**

1. Accounting policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Psoriasis and Psoriatic Arthritis Alliance meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The accounts present information about the company as an individual undertaking and not about its group. The company and its subsidiary undertaking comprise a small-sized group. The company has therefore taken advantage of the exemptions provided by section 398 of the Companies Act 2006 not to prepare group accounts

1.2 Company status

The charity is a company limited by guarantee and has no share capital. Its registered office is 30 Orange Street, London WC2H 7HF. The members of the company are the Trustees named on page 1. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

The financial statements are prepared in sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £.

1.3 Going concern

The trustees have a reasonable expectation that the charity has adequate resources to continue in operation for the foreseeable future and are confident that the charity can continue as a going concern for a period of at least 12 months from the date of approval of these financial statements.

1.4 Income

All income is recognised once the company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

For legacies, entitlement is taken as the earlier of the date on which either: the company is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the company has been notified of the executor's intention to make a distribution. Where legacies have been notified to the company, or the company is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Dividends are recognised once the dividend has been declared and notification has been received by our investment advisor of the investment portfolio.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2023**

1. Accounting policies (continued)

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

Support costs are those costs incurred directly in support of expenditure on the objects of the company and include project management carried out at Headquarters.

Governance costs are those incurred in connection with administration of the company and compliance with constitutional and statutory requirements.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

1.6 Intangible fixed assets and amortisation

Intangible assets are initially recognised at cost and are subsequently measured at cost net of amortisation and any provision for impairment.

Amortisation is provided on intangible fixed assets at rates calculated to write off the cost of each asset, less their estimated residual value, over their expected useful lives on the following bases:

Website cost	- 20% reducing balance
--------------	------------------------

1.7 Tangible fixed assets and depreciation

A review for impairment of a fixed asset is carried out if events or changes in circumstances indicate that the carrying value of any fixed asset may not be recoverable. Shortfalls between the carrying value of fixed assets and their recoverable amounts are recognised as impairments. Impairment losses are recognised in the Statement of financial activities incorporating income and expenditure account.

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Plant and machinery	- 25% reducing balance
Fixtures and fittings	- 25% reducing balance

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2023

1. Accounting policies (continued)

1.8 Fixed asset investments

Fixed asset Investments consists of listed investments and shares in a subsidiary undertaking.

Listed investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised In net income/(expenditure) for the year. Transaction costs are expensed as incurred.

The investment includes the charity's holding in its subsidiary trading company and is shown at cost.

A subsidiary is an entity controlled by the Charity. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.9 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the company; this is normally upon notification of the interest paid or payable by the Bank.

1.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.11 Cash at Bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.12 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

1.13 Financial instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.14 Pensions

The company operates a defined contribution pension scheme and the pension charge represents the amounts payable by the company to the fund in respect of the year.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2023

1. Accounting policies (continued)

1.15 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

1.16 Critical accounting estimates and areas of judgment

In the application of the Charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The Trustees do not consider there to be judgements or estimates that would be considered to be critical to the financial statements.

2. Income from donations and legacies

	Unrestricted funds 2023 £	Total funds 2023 £	<i>Total funds 2022 £</i>
Donations	77,438	77,438	13,226
<i>Total 2022</i>	13,226	13,226	

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2023**

3. Investment income

	Unrestricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
Income from listed investments	16,554	16,554	16,924
Interest receivable	2,413	2,413	539
	<u>18,967</u>	<u>18,967</u>	<u>17,463</u>
<i>Total 2022</i>	<u>17,463</u>	<u>17,463</u>	

4. Analysis of charitable expenditure

	Charitable expenditure 2023 £	Total 2023 £	Total 2022 £
Raising funds:			
Investment management (see note 5)	8,443	8,443	10,556
	<u>8,443</u>	<u>8,443</u>	<u>10,556</u>
Subtotal raising funds			
	<u>8,443</u>	<u>8,443</u>	<u>10,556</u>
Charitable activities:			
Support costs (see note 8)	211,579	211,579	200,995
Direct costs (see note 6)	38,267	38,267	32,490
	<u>249,846</u>	<u>249,846</u>	<u>233,485</u>
Subtotal charitable activities			
	<u>249,846</u>	<u>249,846</u>	<u>233,485</u>
Expenditure on governance (see note 9)	19,209	19,209	15,524
	<u>19,209</u>	<u>19,209</u>	<u>15,524</u>
	<u>277,498</u>	<u>277,498</u>	<u>259,565</u>
<i>Total 2022</i>	<u>259,565</u>	<u>259,565</u>	

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2023**

5. Raising funds

	Unrestricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
Investment management	8,443	8,443	10,556
<i>Total 2022</i>	10,556	10,556	

6. Direct costs

	Information and Support Services £	Total 2023 £	Total 2022 £
Medical consultancy	21,250	21,250	20,000
Printing and stationery	17,017	17,017	12,490
	38,267	38,267	32,490
<i>Total 2022</i>	32,490	32,490	

7. Grants payable

	Total 2023 £	Total 2022 £
No grants were paid in 2023 on in the prior year.		

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2023**

8. Support costs

	Information and Support Services £	Total 2023 £	Total 2022 £
Staff costs	157,494	157,494	149,091
Depreciation	9,762	9,762	12,251
Rent and rates	26,371	26,371	24,185
IT consultancy	11,506	11,506	8,866
Postage	3,599	3,599	2,888
Telephone and fax	463	463	821
Other expenses	913	913	905
Subscriptions	1,471	1,471	1,988
	<u>211,579</u>	<u>211,579</u>	<u>200,995</u>
<i>Total 2022</i>	<u>200,995</u>	<u>200,995</u>	

During the year ended 5 April 2023, the company incurred the following Governance costs:

9. Governance costs

	Unrestricted funds 2023 £	Total funds 2022 £
Accountancy fees	7,470	3,600
Legal and professional	9,916	10,497
Insurance	1,823	1,427
	<u>19,209</u>	<u>15,524</u>

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2023

10. Net gains / (losses) on investments

	2023 £	2022 £
Revaluation of investments	(51,407)	36,882
Gain / (loss) on sale of investments	10,562	11,969
Total	<u>(40,845)</u>	<u>48,851</u>

11. Average number of employees

The average number of persons employed by the company during the year was as follows:

	2023 No.	2022 No.
Administration	4	3

One employee received emoluments totalling £64,400 and a second employee received emoluments of £63,150. This includes national insurance and pension contributions. No other employees received emoluments exceeding £50,000.

12. Independent examiner

The Independent Examiner's remuneration amounts to an Independent Examination fee of £3,600 (2022 - £3,600).

13. Trustees

During the year no trustees (or any persons connected with them) received any remuneration or reimbursed expenses. (2022: £ nil)

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2023**

14. Intangible fixed assets

	Website Costs £
Cost	
At 6 April 2022 and 5 April 2023	75,840
Amortisation	
At 6 April 2022	33,553
Charge for the year	8,457
At 5 April 2023	42,010
Carrying amount	
At 5 April 2023	33,830
At 5 April 2022	42,287

15. Tangible fixed assets

	Plant and machinery £	Fixtures and fittings £	Total £
Cost			
At 6 April 2022 and 5 April 2023	3,543	14,552	18,095
Depreciation			
At 6 April 2022	3,459	9,597	13,056
Charge for the year	21	1,284	1,305
At 5 April 2023	3,480	10,881	14,361
Net book value			
At 5 April 2023	63	3,671	3,734
At 5 April 2022	84	4,955	5,039

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2023**

16. Fixed asset investments

	Listed securities £	Cash in portfolio £	Sub total carried forward £
Market value			
At 6 April 2022	1,067,264	5,432	1,072,696
Additions	9,750	-	9,750
Disposals	(170,088)	-	(170,088)
Valuation changes	(51,407)	-	(51,407)
Withdrawal of cash funds	-	(5,432)	(5,432)
At 5 April 2023	855,519	-	855,519
	Sub total brought forward £	investment in subsidiary £	Total £
Market value			
At 6 April 2022	1,072,696	1	1,072,697
Additions	9,750	-	9,750
Disposals	(170,088)	-	(170,088)
Valuation changes	(51,407)	-	(51,407)
Withdrawal of cash funds	(5,432)	-	(5,432)
At 5 April 2023	855,519	1	855,520

Subsidiary undertakings

The following were subsidiary undertakings of the company:

Name	Holding	2023 £	2022 £
PAPAA Enterprises Limited	100%	1	1
Name	Business	Registered office	
PAPAA Enterprises Limited	Website Licence	Calder & Co 30 Orange Street London WC2H 7HF	

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2023

17. Debtors

	2023 £	2022 £
Other debtors	2,600	2,600
Prepayments and accrued income	881	881
	<u>3,481</u>	<u>3,481</u>

18. Creditors: Amounts falling due within one year

	2023 £	2022 £
Trade creditors	3,053	223
Other taxation and social security	4,382	3,989
Amounts owed to subsidiary undertaking	1	1
Accruals and deferred income	3,840	3,600
	<u>11,276</u>	<u>7,813</u>

19. Statement of funds

Statement of funds - current year

	Balance at 6 April 2022 £	Income £	Expenditure £	Gains/ (Losses) £	Balance at 5 April 2023 £
Designated funds					
Investment and research fund	1,039,600	-	-	-	1,039,600
Small research grant programme	47,000	-	-	-	47,000
	<u>1,086,600</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>1,086,600</u>
General funds					
General Funds	119,975	96,405	(277,498)	(40,845)	(101,963)
Total Unrestricted funds	<u>1,206,575</u>	<u>96,405</u>	<u>(277,498)</u>	<u>(40,845)</u>	<u>984,637</u>
Total of funds	<u>1,206,575</u>	<u>96,405</u>	<u>(277,498)</u>	<u>(40,845)</u>	<u>984,637</u>

The investment and research fund represent sums set aside by the trustees for investments. To earn sufficient income to fund on going research in Psoriasis and Psoriatic Arthritis.

The trustees have decided that a designated fund should be allocated to grants for research. The charity operates an open application small research grant programme, with a maximum award per application of £10,000. The size of the fund allocation (£47,000) reflects the current and anticipated level of applications

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2023

19. Statement of funds (continued)

based on funded projects within the portfolio and that of rejected applications in the current financial year.

It is anticipated that the fund will be spent within each financial year, but awards will only be made based on extensive and thorough vetting of the applications, unused funds will be carried over or used for support, which the trustees proactively identify as meeting with the aims and objectives of the charity.

Statement of funds - prior year

	<i>Balance at 6 April 2021</i>	<i>Income</i>	<i>Expenditure</i>	<i>Gains/ (Losses)</i>	<i>Balance at 5 April 2022</i>
	£	£	£	£	£
Designated funds					
Investment and research fund	1,039,600	-	-	-	1,039,600
Small research grant programme	47,000	-	-	-	47,000
	<u>1,086,600</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>1,086,600</u>
General funds					
General Funds	300,000	30,689	(259,565)	48,851	119,975
Total Unrestricted funds	<u>1,386,600</u>	<u>30,689</u>	<u>(259,565)</u>	<u>48,851</u>	<u>1,206,575</u>
Total of funds	<u>1,386,600</u>	<u>30,689</u>	<u>(259,565)</u>	<u>48,851</u>	<u>1,206,575</u>

20. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2023 £
Intangible fixed assets	33,830
Tangible fixed assets	3,734
Fixed asset investments	855,520
Current assets	102,829
Creditors due within one year	(11,276)
	<u>984,637</u>

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2023**

20. Analysis of net assets between funds (continued)

Analysis of net assets between funds - prior year

	<i>Unrestricted funds 2022 £</i>
Intangible fixed assets	42,287
Tangible fixed assets	5,039
Fixed asset investments	1,072,697
Current assets	94,365
Creditors due within one year	(7,813)
	<u>1,206,575</u>

21. Related party transactions

Remuneration of key management personnel	2023 £	2022 £
Aggregate compensation	<u>64,400</u>	<u>60,033</u>

At the end of the year Psoriasis and Psoriatic Arthritis Alliance owed £1 (2022: £1) to PAPAA Enterprises Limited a wholly owned subsidiary.

THE PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE

England & Wales - Charity number 1118192

Accounts

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE

(A company limited by guarantee)
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2022

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

CONTENTS

	Page
Reference and administrative details of the charity, its trustees and advisers	1
Trustees' report	2 - 9
Independent examiner's report	10 - 11
Statement of financial activities	12
Balance sheet	13
Notes to the financial statements	14 - 26

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 5 APRIL 2022**

Trustees

P.H.S. Von Der Heyde, Chairman
J. M. Peel
C. C. Auld
E.G. Hayes, Treasurer (appointed 1 March 2022)

Company registered number

06074887

Charity registered number

1118192

Registered office

30 Orange Street, London, WC2H 7HF

Accountants

Calder & Co, 30 Orange Street, London, WC2H 7HF

Bankers

Santander Business Banking, PO Box 10102, 21 Prescott Street, London, E1 8TN

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT
FOR THE YEAR ENDED 5 APRIL 2022

The trustees present their report and financial statements for the year ended 5 April 2022.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity's trust deeds, the Charities Act 2011, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective from 1 January 2019).

Objectives and Activities

a. Objectives and activities

(a) The relief of sickness and the preservation of health among people including (but not limited to) those suffering from psoriasis, psoriatic arthropathy and other related or similar conditions;

(b) To promote and protect the physical and mental health of sufferers of psoriasis, psoriatic arthropathy and other related or similar conditions through the provision of financial assistance, support, education and practical advice to sufferers and their families and their carers;

(c) To advance the education of the medical profession, the nursing profession, the media and the general public in all areas relating to psoriasis, psoriatic arthropathy and other related or similar conditions; and

(d) To promote or assist in the promotion of research into the causes, prevention, alleviation and the management of psoriasis, psoriatic arthropathy and other related or similar conditions, and to disseminate the useful results of such research for the public benefit.

The policies adopted in furtherance of these objects are:

(1) To continue to provide support and advice to those affected either directly or indirectly by psoriasis and or psoriatic arthritis.

(2) To actively educate the wider public about the conditions of psoriasis and psoriatic arthritis, by responding to direct contact with the charity and proactively contributing to media and public debates.

(3) To continue developing, updating and providing free educational information in the form of leaflets, pamphlets, other printed material and a comprehensive website.

(4) To investigate what areas of research are being undertaken and where the trustees feel it is appropriate, they will make grants available. Grants are made at the discretion of the trustees and in accordance with the objects of the charity.

There have been no changes to the objects or policies during the year.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2022

Achievements and performance

a. Review of activities

In the previous annual report, the trustees set-out a clear strategy to further establish the charity, by priority areas of work.

These are as follows:

- Raise the knowledge of the conditions at primary care.
- Identify unmet needs.
- Act as a bridge for patients to navigate the NHS pathways.
- Signpost and provide educational support.
- Develop research funding.
- Develop support of parents of children with the disease.
- Expand across all the popular modern media platforms.

To develop these aims the charity engaged in a number of activities that would either expand the work or lead towards implementation in the future. The following had been identified as areas to develop:

- Seek sponsorship/grants to provide FREE access for nurses to PAPAA online training.
- Develop applications to grant giving trusts to support specific projects.
- Increase the charity profile for support at sponsored events.
- Use social media more.
- Develop digital marketing.
- Advertise.
- Awareness campaigns.
- Micro training; transfer written word into interactive training programmes.

Progress

During this financial year the global COVID-19 pandemic continued to impact across society and not least the activities of health-related charities. With many restrictions on movement and gatherings in place, activities and events that charitable organisations would attend or take part, were either cancelled or moved to online video involvement.

The uncertainty of restrictions and rules continues to affect the planning and implementation of strategies. At the latter end of this financial year, it is still fair to say that for charitable organisations the impact remains significant, particularly for planned activities and future aims and objectives. The subsequent uncertainty of other global issues and conflicts, with its impact on cost of living, will only add to the difficulty that charities face post-COVID. This is particularly affecting ongoing fundraising and the chance to generate new income to support the much-needed awareness and patient support activities.

The charity and staff continued to follow Government guidelines around social distancing, mask wearing and working from home remotely. The abrupt nature of the original stay-at-home instructions of March 2020, forced a change in working and service delivery. As an agile organisation, the charity adapted and, in some instances, was able to be involved in activities that previously would have been prohibitive due to location and cost of attendance. This enforced change provided the opportunity to continue to support the charity's constituent group, and to a wider audience. The future appears to be leaning towards hybrid events. The charity will monitor such activities and has and will continue to embrace the changing environment to best serve its constituent group.

The use of Zoom conferencing with regular staff catch-ups, which was established during the initial phases of the lockdown, has become an embedded part of the working day and a valuable aid to work practices with colleagues and external agencies.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2022

The impact on distribution continued during this financial year, as many clinics were still not seeing patients face-to-face and paper material was still not on public display. The activity began to return, but not to the previous levels seen before the pandemic. The impact on the distribution of the bi-annual Skin 'n' Bones Connection journal continued, with distribution still limited to subscribers and downloads via the PAPAA shop.

Key activities

Although the trustees' plans were interrupted, where activities could be progressed there has been substantial advancement. The first phase was the completion to facilitate the process of receiving donations. This included an obvious 'donate' button on all pages on the website, allowing people to make direct donations. These can be anonymous, named or as a dedicated page for an event with donations being paid directly to the charity. It also allows GiftAid to be added to donations.

In the donation pages the presentations have been enhanced with images and further links to other ways to support PAPAA. The inclusion of 'widgets' to make click through easier has also been added, as has the Fundraiser Regulator logo, which provides details of our ethical approach to fundraising. Further 'widgets' were explored including a link to receive donations from Amazon (called Amazon Smile) and eBay for charity as a nominated good cause following a listing. Donations via PayPal Giving, were received and interest in promotional awareness items, such as our magazine and wristbands etc. have also increased.

As part of the process of raising the charity's identity as a 'good cause' and to support and provide messages that people will identify with, we've reviewed our impact report of achievements, as follows:

- The most comprehensive psoriatic disease specific website in the UK, with nearly 10,000 free to access items and pages.
- A range of 23 printed leaflets on the core aspects of psoriasis and psoriatic arthritis, with more than 200,000 distributed free in the last 10-years.
- More than 1,000 health care professionals provided with free patient support material.
- Supported 3,500 UK pharmacies to provide free patient resource at the point of medicine delivery.
- Biannual journal called Skin 'n' Bones Connection regularly distributed since 1993 to patients and a wide range of healthcare providers.
- Engaged and represented patient views with UK regulators including NICE, SMC, AWMSG and the MHRA to provide input into new drug appraisals and regulatory affairs.
- Actively engaged across the most popular social media applications, with around 10,000 interactions.
- Gathered real stories via our engagement group and PAPAA surveys with more than 5,000 individual views and suggestions from lived-experience of psoriatic disease.
- Around three-quarters of a million pounds provided to support research and training initiatives in psoriatic disease.
- Regular updates provided via an eNewsletter to more than 1,400 people.
- Trained multidisciplinary healthcare professional via our CPD accredited Psoriasis in Practice programme, with many subsidised to access the training at no cost.
- Provided anonymised access to peer-support to those often desperate for someone to listen and hear their voice.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2022

The next phase of activity was to develop a short promotional video, which was embeded in the main donation landing page and posted across our social media pages and YouTube channel.

A campaign slogan was developed to provide a simple message strapline to convey what PAPAA does under the words 'CARE - CAUSE - CURE'

- Care = Support and education – information, website, training programmes/events.
- Cause = Research – funding relevant aligned projects.
- Cure = Facilitating the conversation to meet peoples' needs.

Further work to support that activity, has been developed with the ambition include:

- Raising visibility and profile of the charity and disease.
- Further develop information and support material.
- Review and continue to keep website accurate.
- Improve and expand professional training.
- Develop fundraising strategies to increase donations.
- Provide research funding and support.
- Continue external engagement with relevant agencies.

Differential and collaborative activities

In discussion with colleagues the charity has explored defining a clear role of how best it can support work that can complement others working in similar or associated conditions. This has included exploring a number of ideas of how to develop collaborations or joint work with other groups.

Building on the becoming a partner in the Connect Immune Research initiative, which is a collective of type 1 diabetes charity JDRF, MS Society, and Versus Arthritis with support partner the British Society for Immunology, the intention is to learn how immune disorders are linked, for the charity, this was seen as a first step to achieving an effective collaborative approach. Further work has taken place to involve the charity in wider activities.

Psoriasis in Practice

The charity's online course, now in version 7, was once again updated and fully reviewed by Julie Van Onselen and reaccruited by the Royal College of Nursing until 29 April 2022. In the review the following feedback was provided. "This is an excellent educational package that represents exemplary educational practices and encourages proactive engagement and learning. It is reapproved for accreditation."

Research funding

Supporting well run research projects under a small grants scheme continued, those already funded projects were severely delayed by re-deployment of researchers to work on the COVID-19 virus. No cost extensions were granted to aid the recipients to complete and publish their work. Enquiries for funding continued to be received and the trustees applied their usual rigorous standards and tests to decide whether the applications merited a grant award.

The following continue to be the main areas of interest to the trustees:

- Short term observational studies.
- Funding of feasibility and pilot studies.
- Systematic reviews.
- Small epidemiological surveys.
- Psoriasis and psoriatic arthritis in children.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2022

PAPAA continues to hold partner status with the National Institute for Health Research (NIHR), which allows eligible research projects to be included in the NIHR Clinical Research Network Portfolio and therefore able to access NHS support via the NIHR Clinical Research Network infrastructure. Further support of relevant research will continue.

Trusted information provider

The Patient Information Forum (PIF) is the UK membership organisation and network for people working in health information and support. As the independent voice of UK health information, PIF provides an accredited process to recognise trusted information providers, called the PIF TICK. Full accreditation was re-awarded to PAPAA, in October 2021 to certify that charity had met the requirements of the PIF TICK quality mark for health information.

Ethical fundraising

As part of awareness and fundraising development, the charity continues to be a member of the Fundraising Regulator, to provide transparency and clear guide to the public about the way in which we will manage our fundraising activities.

External activities

Collaboration and involvement with other organisations and external agencies are seen by the charity trustees as an important part of the advocacy and representation of the organisation's constituent group. This includes work with the Priority Setting Partnership with the James Lind Alliance, the British Association of Dermatologists, and The British Society for Rheumatology. Staff continue to respond to requests for support and to provide the patient lived-experience of psoriasis and psoriatic arthritis.

Data and evidence gathering

An ongoing process of data and evidence gathering and analysis of user issues, along with strategic distribution of electronic surveys and a standing open access PAPAA survey, have built a broad view of the needs of the constituent group the charity represents.

The use of this original generally unpublished data aided the submission of the patient's 'lived experience' to the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All-Wales Medicines Strategy Group (AWMSG) to drug appraisals for new medicines; the process has proven to be very valuable and provide a real-life perspective. Positive feedback was received following submissions, with the charity's approach being formally appreciated by the Patient and Public Engagement teams of the respective agencies.

Responding to calls from medicine agencies is seen as an important PAPAA representation role. This has also included proactive engagement by raising alarms and alerts to the Medicines Health Regulator Authority (MHRA), regarding misleading advertising, inappropriate promotion of psoriasis and psoriatic arthritis products, and where fake or adulterated medicine is being made available. This work is jointly from evaluation of the area of operation and through direct contact from people with the condition. This close engagement has also seen invitations to contribute to safety campaigns that provided a wider benefit beyond our area of work, by also providing a public benefit.

Unmet needs

We have continued to engage with our constituent group particularly via our 'your views' and 'share your story' sections of our website. Regular surveys have allowed us to identify areas and themes that are important to patients. Analysis of website search terms and activity along with direct interaction with people has identified a

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2022

number of topics where exploration is required. This work continues to influence the production of new content and support activities.

Public and patient engagement

This has become an important part of our work and aligns with growing expectation that charities need to demonstrate how their work is influenced by those they serve. PAPAA is continuing to engage with patients and the public in order to help our patient-centred approach to provide support based on need. We have an active user group that provides input and support.

Core work

Apart from the forward planning ambitions of the charity, there still remains core day-to-day activities that continue to be carried out in support of people affected by psoriasis and psoriatic arthritis, these include:

- Responding to all enquiry routes.
- Maintaining and monitoring website activity.
- Proactively engaging with users.
- Seeking ways to raise funds.
- Actively raising awareness and promoting the charity.
- Engaging in external events.
- Social media postings.
- Horizon scanning of latest developments.
- Producing and monitoring publications.

Public benefit

Supporting people to understand psoriasis and psoriatic arthritis and raise awareness to a wider audience has continued to be part of the work of the charity. Providing realistic support, that is backed by evidence and scientific rigour is key to that support. The role of meeting all those affected needs from cradle to grave also continues to be of the utmost importance.

Privacy and security

A policy of open access to a confidential and anonymous helpline, has also been maintained. The support that is given generally follows a peer-to-peer approach of listening, showing empathy and then directional advice of how to get the most out of the services provided within the NHS framework. This work, although, often intense and in-depth, is often praised by service users as a useful and effective approach to supporting them in what can be a very difficult period, whether newly diagnosed or entering a different phase of life or disease stage. The ability to provide time, resource and signposting is also valued, with returning calls to seek further support often taking place. The charity maintains the highest level of awareness towards the well-being, privacy and security of the information provided by those it engages with, as set out in the General Data Protection Regulation (GDPR).

Conclusion

In what continued to be a difficult year for society, the charity was able to continue to provide a full range of support and services, not only to its constituent group, but also to the wider public. The impact and curtailing of plans on income generation and other activities saw a lower than expected income stream, whilst more demand for support continued. The charity was able to use its reserves to continue to provide the support and services to all those who needed them. It is clear that COVID-19 has had a detrimental effect on the global economy, this will further continue to impact the work of the charitable sector, where income generation may not be able to match the growing needs of those who need their support.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2022

The trustees and those involved with the charity, will aim to provide all that is possible to continue to help those affected by psoriasis and psoriatic arthritis, particularly during these uncertain and challenging times.

Financial review

a. Reserves policy

In line with the guidance set out by the Charities Commission the Trustees have developed the following reserves policy to inform donors, funders and other stakeholders on how funds are being used to support the charity's aims and objectives.

The charity has previously used funds to generate income and also drawn on those funds to support its activities. A low risk balanced approach has been used to achieve this. The fund is now reducing and the Trustees are actively developing activities to generate new streams of income, whilst mindful of the need to use existing funds wisely, until such activities are able to support the work that is needed to support the charity's constituent group.

The cost of running the charity's activities is estimated to be approximately £300,000 per annum. Given that the charity provides its services and support free of charge, with only a small cost to cover the subscription to receive the journal via the post, reliance on the reserve is vital in the current climate to support activities.

Voluntary income through donations, regular gifts and legacies is a small part of the charity's income, therefore until new and regular income streams have been developed it is anticipated that further reliance on the reserve will be vital to maintain the current activities and the development of new much needed initiatives.

The current funds held by the charity at the end of the financial year are £1,206,575. Prudent management will continue in order to generate income, both to support daily activities with some provision to release funds to support the research activities and provide small grants to researchers working in the areas of ongoing interest to the Trustees. The allocation for research is anticipated to be around £60,000 per annum, dependent on applications being of a high standard and likely to provide meaningful results that add scientific value.

This policy is regularly monitored and reviewed for effectiveness in the light of the changing funding and financial climate and other risks by the Board of Trustees. It is adjusted accordingly as plans, opportunities and income streams emerge.

b. Designated funds

The trustees have decided that a designated fund should be allocated to grants for research. The charity operates an open application small research grant programme, with a maximum award per application of £10,000.

The size of the fund allocation is £60,000 per financial year, which reflects the current and anticipated level of applications based on funded projects within the portfolio and that of rejected applications in the current financial year.

It is anticipated that the fund will be spent within each financial year, if not the funds will be carried forward to create a rolling offer, or used for support, which the trustees proactively identify as meeting with the aims and objectives of the charity. Awards will only be made based on extensive and thorough vetting of the applications.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2022

Structure, governance and management

a. Constitution

The Charity is a charitable company limited by guarantee and was incorporated on 30 January 2007. The company took over the assets, liabilities and activities of the Psoriasis Support Trust, an unincorporated charity, on 6 April 2007 and of the Psoriatic Arthropathy Alliance charitable company limited by guarantee on 3 April 2009 as agreed by the trustees of both charities.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

P.H.S. Von Der Heyde (Chairman)
J. M. Peel
C. C. Auld
E.G. Hayes (Treasurer) (From March 2022)
B. Lindsey (Deceased March 2021)

This report was approved by the Trustees, on 23 January 2023 and signed on their behalf by:

Paul v. der Heyde

.....
P.H.S. Von Der Heyde

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 5 APRIL 2022

Independent examiner's report to the Trustees of Psoriasis and Psoriatic Arthritis Alliance (the 'company')

I report to the trustees (who are also Directors for the purpose of company law) on my examination of the accounts of the company for the year ended 5 April 2022 which comprise the Statement of Financial Activities, the Balance Sheet and related notes.

This report is made solely to the charity's trustees, as a body, in accordance with section 145 of the Charities Act 2011. My work has been undertaken so that I might state to the charity's trustees those matters I am required to state to them in this report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for my work, for this report, or for the opinions I have formed.

Responsibilities and basis of report

As the Trustees of the company (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charitable company's financial statements carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

An independent examination does not involve gathering all the evidence that would be required in an audit and consequently does not cover all the matters that an auditor considers in giving their opinion on the financial statements. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide. Consequently I express no opinion as to whether the financial statements present a 'true and fair' view and my report is limited to those specific matters set out in the independent examiner's statement.

Independent examiner's statement


I have completed my examination. I can confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

INDEPENDENT EXAMINER'S REPORT (continued)
FOR THE YEAR ENDED 5 APRIL 2022

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed: 

Dated: 23 January 2023

A Koupland ACA

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**STATEMENT OF FINANCIAL ACTIVITIES INCORPORATING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 5 APRIL 2022**

	Note	Unrestricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Income from:				
Donations and legacies	2	13,226	13,226	10,343
Investments	3	17,463	17,463	20,836
Total income		30,689	30,689	31,179
Expenditure on:				
Raising funds	5	10,556	10,556	9,587
Other charitable activities		249,009	249,009	280,255
Total expenditure	4	259,565	259,565	289,842
Net expenditure before investment gains		(228,876)	(228,876)	(258,663)
Net gains / (losses) on investments	10	48,851	48,851	174,237
Net expenditure before other recognised gains and losses		(180,025)	(180,025)	(84,426)
Net movement in funds		(180,025)	(180,025)	(84,426)
Reconciliation of funds:				
Total funds brought forward		1,386,600	1,386,600	1,471,026
Total funds carried forward		1,206,575	1,206,575	1,386,600

The notes on pages 14 to 26 form part of these financial statements.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)
REGISTERED NUMBER: 06074887

BALANCE SHEET
AS AT 5 APRIL 2022

	Note	£	2022 £	£	2021 £
Fixed assets					
Intangible assets	14		42,287		52,859
Tangible assets	15		5,039		6,718
Investments	16		1,072,697		1,137,478
			<u>1,120,023</u>		<u>1,197,055</u>
Current assets					
Debtors	17	3,481		3,481	
Cash at bank and in hand		90,884		212,857	
		<u>94,365</u>		<u>216,338</u>	
Creditors: amounts falling due within one year	18	(7,813)		(26,793)	
Net current assets			<u>86,552</u>		<u>189,545</u>
Net assets			<u>1,206,575</u>		<u>1,386,600</u>
Charity Funds					
Unrestricted funds	19		1,206,575		1,386,600
Total funds			<u>1,206,575</u>		<u>1,386,600</u>

The company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The Trustees consider that the company is entitled to exemption from the requirement to have an audit under the provisions of section 477 of the Companies Act 2006 ("the Act") and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Act.

The Trustees acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements were approved and authorised for issue by the Trustees on 23 January 2023 and signed on their behalf, by:

Paul v.der Heyde

.....
P.H.S. Von Der Heyde

The notes on pages 14 to 26 form part of these financial statements.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2022

1. Accounting policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Psoriasis and Psoriatic Arthritis Alliance meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The accounts present information about the company as an individual undertaking and not about its group. The company and its subsidiary undertaking comprise a small-sized group. The company has therefore taken advantage of the exemptions provided by section 398 of the Companies Act 2006 not to prepare group accounts

1.2 Company status

The charity is a company limited by guarantee and has no share capital. Its registered office is 30 Orange Street, London WC2H 7HF. The members of the company are the Trustees named on page 1. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

The financial statements are prepared in sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £.

1.3 Going concern

The trustees have a reasonable expectation that the charity has adequate resources to continue in operation for the foreseeable future and are confident that the charity can continue as a going concern for a period of at least 12 months from the date of approval of these financial statements.

1.4 Income

All income is recognised once the company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

For legacies, entitlement is taken as the earlier of the date on which either: the company is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the company has been notified of the executor's intention to make a distribution. Where legacies have been notified to the company, or the company is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Dividends are recognised once the dividend has been declared and notification has been received by our investment advisor of the investment portfolio.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2022

1. Accounting policies (continued)

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

Support costs are those costs incurred directly in support of expenditure on the objects of the company and include project management carried out at Headquarters.

Governance costs are those incurred in connection with administration of the company and compliance with constitutional and statutory requirements.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

1.6 Intangible fixed assets and amortisation

Intangible assets are initially recognised at cost and are subsequently measured at cost net of amortisation and any provision for impairment.

Amortisation is provided on intangible fixed assets at rates calculated to write off the cost of each asset, less their estimated residual value, over their expected useful lives on the following bases:

Website cost	- 20% reducing balance
--------------	------------------------

1.7 Tangible fixed assets and depreciation

A review for impairment of a fixed asset is carried out if events or changes in circumstances indicate that the carrying value of any fixed asset may not be recoverable. Shortfalls between the carrying value of fixed assets and their recoverable amounts are recognised as impairments. Impairment losses are recognised in the Statement of financial activities incorporating income and expenditure account.

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Plant and machinery	- 25% reducing balance
Fixtures and fittings	- 25% reducing balance

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2022

1. Accounting policies (continued)

1.8 Fixed asset investments

Fixed asset Investments consists of listed investments and shares in a subsidiary undertaking.

Listed investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised In net income/(expenditure) for the year. Transaction costs are expensed as incurred.

The investment includes the charity's holding in its subsidiary trading company and is shown at cost.

A subsidiary is an entity controlled by the Charity. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.9 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the company; this is normally upon notification of the interest paid or payable by the Bank.

1.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.11 Cash at Bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.12 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

1.13 Financial instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.14 Pensions

The company operates a defined contribution pension scheme and the pension charge represents the amounts payable by the company to the fund in respect of the year.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2022

1. Accounting policies (continued)

1.15 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

1.16 Critical accounting estimates and areas of judgment

In the application of the Charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The Trustees do not consider there to be judgements or estimates that would be considered to be critical to the financial statements.

2. Income from donations and legacies

	Unrestricted funds 2022 £	Total funds 2022 £	<i>Total funds 2021 £</i>
Donations	13,226	13,226	10,343
<i>Total 2021</i>	<i>10,343</i>	<i>10,343</i>	

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2022**

3. Investment income

	Unrestricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Income from listed investments	16,924	16,924	16,868
Interest receivable	539	539	3,968
	<u>17,463</u>	<u>17,463</u>	<u>20,836</u>
<i>Total 2021</i>	<u>20,836</u>	<u>20,836</u>	

4. Analysis of charitable expenditure

	Charitable expenditure 2022 £	Total 2022 £	Total 2021 £
Raising funds:			
Investment management (see note 5)	10,556	10,556	9,587
	<u>10,556</u>	<u>10,556</u>	<u>9,587</u>
Charitable activities:			
Support costs (see note 8)	200,995	200,995	217,279
Direct costs (see note 6)	32,490	32,490	26,872
Grant funding of activities (see note 7)	-	-	8,500
	<u>233,485</u>	<u>233,485</u>	<u>252,651</u>
Expenditure on governance (see note 9)	<u>15,524</u>	<u>15,524</u>	<u>27,604</u>
	<u>259,565</u>	<u>259,565</u>	<u>289,842</u>
<i>Total 2021</i>	<u>289,842</u>	<u>289,842</u>	

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2022

5. Raising funds

	Unrestricted funds 2022 £	Total funds 2022 £	<i>Total funds 2021 £</i>
Investment management	10,556	10,556	9,587
<i>Total 2021</i>	9,587	9,587	

6. Direct costs

	Information and Support Services £	Total 2022 £	<i>Total 2021 £</i>
Medical consultancy	20,000	20,000	20,303
Printing and stationery	12,490	12,490	6,231
Contribution to PAPAA Enterprises Limited	-	-	338
	32,490	32,490	26,872
<i>Total 2021</i>	26,872	26,872	

7. Grants payable

	Total 2022 £	<i>Total 2021 £</i>
The University of Liverpool	-	8,500
<i>Total 2021</i>	8,500	

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2022

8. Support costs

	Information and Support Services £	Total 2022 £	Total 2021 £
Staff costs	149,091	149,091	146,257
Depreciation	12,251	12,251	25,108
Rent and rates	24,185	24,185	24,010
IT consultancy	8,866	8,866	12,359
Postage	2,888	2,888	4,563
Telephone and fax	821	821	2,352
Other expenses	905	905	926
Subscriptions	1,988	1,988	504
Training costs	-	-	1,200
	<u>200,995</u>	<u>200,995</u>	<u>217,279</u>
<i>Total 2021</i>	<u>217,279</u>	<u>217,279</u>	

The 2021 depreciation charge of £25,108 includes an amount of £9,766 that related to the 2020 depreciation charge of charities intangible fixed assets

During the year ended 5 April 2022, the company incurred the following Governance costs:

9. Governance costs

	Unrestricted funds 2022 £	Total funds 2021 £
Accountancy fees	3,600	2,900
Legal and professional	10,497	23,419
Insurance	1,427	1,285
	<u>15,524</u>	<u>27,604</u>

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2022

10. Net gains / (losses) on investments

	2022	<i>2021</i>
	£	£
Revaluation of investments	36,882	<i>161,111</i>
Gain / (loss) on sale of investments	11,969	<i>13,126</i>
Total	48,851	<i>174,237</i>

11. Average number of employees

The average number of persons employed by the company during the year was as follows:

	2022	<i>2021</i>
	No.	<i>No.</i>
Administration	3	<i>3</i>

Two employees received emoluments totalling £60,033. This includes national insurance and pension contributions. No other employees received emoluments exceeding £50,000.

12. Independent examiner

The Independent Examiner's remuneration amounts to an Independent Examination fee of £3,600 (2021 - £2,900).

13. Trustees

During the year no trustees (or any persons connected with them) received any remuneration or reimbursed expenses. (2021: £ nil)

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2022

14. Intangible fixed assets

	Website Costs £
Cost	
At 6 April 2021 and 5 April 2022	75,840
Amortisation	
At 6 April 2021	22,981
Charge for the year	10,572
At 5 April 2022	33,553
Carrying amount	
At 5 April 2022	42,287
<i>At 5 April 2021</i>	52,859

15. Tangible fixed assets

	Plant and machinery £	Fixtures and fittings £	Total £
Cost			
At 6 April 2021 and 5 April 2022	3,543	14,552	18,095
Depreciation			
At 6 April 2021	3,431	7,946	11,377
Charge for the year	28	1,651	1,679
At 5 April 2022	3,459	9,597	13,056
Net book value			
At 5 April 2022	84	4,955	5,039
<i>At 5 April 2021</i>	112	6,606	6,718

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2022

16. Fixed asset investments

	Listed securities £	Cash in portfolio £	Sub total carried forward £
Market value			
At 6 April 2021	1,102,132	35,345	1,137,477
Additions	10,503	(10,503)	-
Disposals	(82,253)	94,222	11,969
Dividends and other income from investments	-	16,924	16,924
Valuation changes	36,882	-	36,882
Management fees	-	(10,556)	(10,556)
Withdrawal of cash funds	-	(120,000)	(120,000)
	<u>1,067,264</u>	<u>5,432</u>	<u>1,072,696</u>
At 5 April 2022	<u>1,067,264</u>	<u>5,432</u>	<u>1,072,696</u>
	Sub total brought forward £	investment in subsidiary £	Total £
Market value			
At 6 April 2021	1,137,477	1	1,137,478
Disposals	11,969	-	11,969
Dividends and other income from investments	16,924	-	16,924
Valuation changes	36,882	-	36,882
Management fees	(10,556)	-	(10,556)
Withdrawal of cash funds	(120,000)	-	(120,000)
	<u>1,072,696</u>	<u>1</u>	<u>1,072,697</u>
At 5 April 2022	<u>1,072,696</u>	<u>1</u>	<u>1,072,697</u>

Subsidiary undertakings

The following were subsidiary undertakings of the company:

Name	Holding	2022 £	2021 £
PAPAA Enterprises Limited	100%	1	1

Name	Business	Registered office
PAPAA Enterprises Limited	Website Licence	Calder & Co 30 Orange Street London WC2H 7HF

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2022**

17. Debtors

	2022	<i>2021</i>
	£	£
Other debtors	2,600	<i>2,600</i>
Prepayments and accrued income	881	<i>881</i>
	3,481	<i>3,481</i>

18. Creditors: Amounts falling due within one year

	2022	<i>2021</i>
	£	£
Trade creditors	223	<i>3,733</i>
Other taxation and social security	3,989	<i>4,457</i>
Amounts owed to subsidiary undertaking	1	<i>1</i>
Accruals and deferred income	3,600	<i>18,602</i>
	7,813	<i>26,793</i>

19. Statement of funds

Statement of funds - current year

	Balance at 6 April 2021	Income	Expenditure	Gains/ (Losses)	Balance at 5 April 2022
	£	£	£	£	£
Designated funds					
Investment and research fund	1,039,600	-	-	-	1,039,600
Small research grant programme	47,000	-	-	-	47,000
	1,086,600	-	-	-	1,086,600
General funds					
General Funds	300,000	30,689	(259,565)	48,851	119,975
Total Unrestricted funds	1,386,600	30,689	(259,565)	48,851	1,206,575
Total of funds	1,386,600	30,689	(259,565)	48,851	1,206,575

The investment and research fund represent sums set aside by the trustees for investments. To earn sufficient income to fund on going research in Psoriasis and Psoriatic Arthritis.

The trustees have decided that a designated fund should be allocated to grants for research. The charity operates an open application small research grant programme, with a maximum award per application of £10,000. The size of the fund allocation (£47,000) reflects the current and anticipated level of applications

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2022

19. Statement of funds (continued)

based on funded projects within the portfolio and that of rejected applications in the current financial year.

It is anticipated that the fund will be spent within each financial year, but awards will only be made based on extensive and thorough vetting of the applications, unused funds will be carried over or used for support, which the trustees proactively identify as meeting with the aims and objectives of the charity.

Statement of funds - prior year

	<i>Balance at 6 April 2020</i>	<i>Income</i>	<i>Expenditure</i>	<i>Transfers in/out</i>	<i>Gains/ (Losses)</i>	<i>Balance at 5 April 2021</i>
	£	£	£	£	£	£
Designated funds						
Investment and research fund	1,115,956	1,505	-	(77,861)	-	1,039,600
Small research grant programme	47,000	-	-	-	-	47,000
	<u>1,162,956</u>	<u>1,505</u>	<u>-</u>	<u>(77,861)</u>	<u>-</u>	<u>1,086,600</u>
General funds						
General Funds	308,070	29,674	(289,842)	77,861	174,237	300,000
Total Unrestricted funds	<u>1,471,026</u>	<u>31,179</u>	<u>(289,842)</u>	<u>-</u>	<u>174,237</u>	<u>1,386,600</u>
Total of funds	<u><u>1,471,026</u></u>	<u><u>31,179</u></u>	<u><u>(289,842)</u></u>	<u><u>-</u></u>	<u><u>174,237</u></u>	<u><u>1,386,600</u></u>

20. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2022 £
Intangible fixed assets	42,287
Tangible fixed assets	5,039
Fixed asset investments	1,072,697
Current assets	94,365
Creditors due within one year	(7,813)
	<u><u>1,206,575</u></u>

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2022

20. Analysis of net assets between funds (continued)

Analysis of net assets between funds - prior year

	<i>Unrestricted funds 2021 £</i>
Intangible fixed assets	52,859
Tangible fixed assets	6,718
Fixed asset investments	1,137,478
Current assets	216,338
Creditors due within one year	(26,793)
	1,386,600

21. Related party transactions

Remuneration of key management personnel	2022	2021
	£	£
Aggregate compensation	60,033	57,679

Psoriasis and Psoriatic Arthritis Alliance has licensed the use of eTips website to PAPAA Enterprises Limited a wholly owned subsidiary. This activity is within the objects of the charity and therefore considered to be primary purpose trading. At the end of the year Psoriasis and Psoriatic Arthritis Alliance owed £1 (2021: £1) to PAPAA Enterprises Limited and contributed £398 (2021: £398) towards the website.

THE PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE

England & Wales - Charity number 1118192

Accounts

Charity Registration No. 1118192

Company Registration No. 06074887 (England and Wales)

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE

(A COMPANY LIMITED BY GUARANTEE)

ANNUAL REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 5 APRIL 2021

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Paul Von Der Heyde (Chairman) J. M. Peel C. C. Auld
Secretary	Fisher Secretaries Limited
Charity number	1118192
Company number	06074887
Principal address	Acre House 11-15 William Road London NW1 3ER United Kingdom
Auditor	Xeinadin Audit Limited Chartered Accountants and Registered Auditors Dalton House 9 Dalton Square Lancaster LA1 1WD
Bankers	Santander Business Banking PO Box 10102 21 Prescott Street London E1 8TN
Solicitors	Wilsons Solicitors Steynings House Summerlock Approach Salisbury Wiltshire SP2 7RJ

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
CONTENTS

	Page
Trustees' report	1 - 6
Statement of trustees' responsibilities	7
Independent auditor's report	8 - 9
Statement of financial activities	10
Balance sheet	11
Notes to the financial statements	12 - 21

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)
FOR THE YEAR ENDED 5 APRIL 2021

The trustees present their report and financial statements for the year ended 5 April 2021.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity's trust deeds, the Charities Act 2011, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective from 1 January 2019).

Objectives and activities

The Charity's objects are:
(a) The relief of sickness and the preservation of health among people including (but not limited to) those suffering from psoriasis, psoriatic arthropathy and other related or similar conditions;
(b) To promote and protect the physical and mental health of sufferers of psoriasis, psoriatic arthropathy and other related or similar conditions through the provision of financial assistance, support, education and practical advice to sufferers and their families and their carers;
(c) To advance the education of the medical profession, the nursing profession, the media and the general public in all areas relating to psoriasis, psoriatic arthropathy and other related or similar conditions; and
(d) To promote or assist in the promotion of research into the causes, prevention, alleviation and the management of psoriasis, psoriatic arthropathy and other related or similar conditions, and to disseminate the useful results of such research for the public benefit.
The policies adopted in furtherance of these objects are:
(1) To continue to provide support and advice to those affected either directly or indirectly by psoriasis and or psoriatic arthritis.
(2) To actively educate the wider public about the conditions of psoriasis and psoriatic arthritis, by responding to direct contact with the charity and proactively contributing to media and public debates.
(3) To continue developing, updating and providing free educational information in the form of leaflets, pamphlets, other printed material and a comprehensive website.
(4) To investigate what areas of research are being undertaken and where the trustees feel it is appropriate, they will make grants available. Grants are made at the discretion of the trustees and in accordance with the objects of the charity.
There have been no changes to the objects or policies during the year.

Achievements and performance

In the previous annual report, the trustees set-out a clear strategy to further establish the charity, by priority areas of work.

These are as follows:

- Raise the knowledge of the conditions at primary care
- Identify unmet needs
- Act as a bridge for patients to navigate the NHS pathways
- Signpost and provide educational support
- Develop research funding
- Develop support of parents of children with the disease
- Expand across all the popular modern media platforms

To develop these aims the charity engaged in a number of activities that would either expand the work or lead towards implementation in the future. The following had been identified as areas to develop:

- Seek sponsorship/grants to provide FREE access for nurses to PAPAA online training
- Develop applications to grant giving trusts to support specific projects

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2021

- Increase the charity profile for support at sponsored events (London marathon etc.)
- Use social media more
- Develop digital marketing
- Advertise
- Awareness campaigns
- Micro training; transfer written word into interactive training programmes

Two main actions were agreed:

1. Explore further the website data and provide analysis to determine performance, particularly the revisiting users versus new user.
2. Develop ideas for projects that could attract funds or be used to apply for grants from trusts, charities and government funding.

The development of these tasks was stalled due to the international identification of the COVID-19 virus at the beginning of 2020. It is fair to say that it was not expected that the global pandemic and subsequent restrictions would have either lasted as long or have the extended impact across all sectors of society. It is equally fair to say that for charitable organisations the impact was significant, particularly for planned activities and future aims and objectives.

In line with many businesses and organisations, from 23 March 2020, following national government instruction, the PAPAA team of staff were required to relocate to 'working from home' (WFH). Therefore, moving into the year beginning 6th April 2020, the charity was working remotely and needed to adapt to the circumstances and continue to support its constituent group.

As a small team and having developed 'tasks and processes' for activities, the staff were able, after initial interruption, set-up WFH quickly and to continue to offer support services. The previous decision to update the IT infrastructure and move to remote login and access to emails and cloud phone services, made remote work easier, although not ideal.

The use of Zoom conferencing with daily staff catch-ups was established and allowed the protection needed for staff to operate safely. A main task that had to be suspended was the distribution of printed information to healthcare settings, as many clinics stopped seeing patients face-to-face and paper material was removed from public display. This impacted too on the distribution of the bi-annual Skin 'n' Bones Connection journal.

An initial impact of the pandemic was an increase in helpline enquiries from people affected by psoriasis and psoriatic arthritis and how the virus was likely to affect them. At the time there was little information, but with Dr David Ashton's support an initial piece of information was added to the news section of the website, with links to trusted sources. The page became the most accessed page (34%) on the website during most of 2020. A subsequent FAQs page was developed to include information about vaccines and further links to sources of information to help people make decisions and assess risks.

During the same period of time the National Institute of Health and Care Excellence (NICE), started to develop rapid guidance to support and inform both patients and healthcare professionals about COVID -19. PAPAA as a previously important stakeholder was invited to be involved. The urgency of the situation required quick response to requests over short-time period. The National Institute of Health Research (NIHR) also sought input from those working within the voluntary sector to review research applications related to COVID-19 treatment and care, these also required rapid turnaround. PAPAA contributed significant input into the review process as part of the national emergency and call for support.

The move towards virtual work and in particular attendance of meetings accelerated; we were unable to attend meetings in person, with most meetings moved to online only. These were via the various video conferencing systems. This has proved to be advantageous in some circumstances, as it has allowed the charity to be represented at events that in the past would have been prohibitive due to location and cost to attend. The disadvantages and shortcoming of virtual participation was outweighed by the ability to be actively involved and engaged. This has proven to be a useful outcome and raised the profile of the charity, therefore fulfilling the trustees' aim of raising awareness of both the condition and organisations work and activities.

The role of healthcare providers is also seen as a vital part of the charity's role, with an ongoing process of support and supply of educational material to aid patients. Distribution is mainly aimed at secondary care specialist centres, but also a large piece of work is with community pharmacists, who provide awareness of the charity's services at the point of delivery of medicines.

The Psoriasis in Practice healthcare professional online Continuing Professional Development (CPD) training programme continued to be accessed and reaccreditation was achieved again from the Royal College for Nursing professional accreditation centre.

As a former member of the NHS England Information Standard scheme, which ended in 2018, the charity applied to the Patient Information Forum (PIF). PIF is the UK membership organisation and network for people working in health information and support.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2021

As the independent voice of UK health information, PIF have developed a replacement called the PIF TICK. Full accreditation was awarded in September 2020 to certify that PAPAA had met the requirements of the PIF TICK quality mark for health information.

As part of awareness and fundraising development, we are a member of the Fundraising Regulator, to provide transparency and clear guide to the public about the way in which we will manage our fundraising activities.

In our drive to fulfil our aims, objectives and wider public benefit a retrospective review took place to demonstrate the achievements so far and to provide a future benchmark.

The following are part of our impact statement:

- The most comprehensive psoriatic disease specific website in the UK, with nearly 10,000 free to access items and pages.
- A range of 23 printed accredited leaflets on the core aspects of psoriasis and psoriatic arthritis, with more than 200,000 distributed free in the last 10-years.
- More than 1,000 healthcare professionals provided with free patient support material.
- Supported 3,500 UK pharmacies to provide free patient resource at the point of medicine delivery.
- Biannual journal called Skin 'n' Bones Connection regularly distributed since 1993 to patients and a wide range of healthcare providers.
- Engaged and represented patient views with UK regulators including National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All-Wales Medicines Strategy Group (AWMSG) and the Medicines & Healthcare products Regulatory Agency (MHRA) to provide input into new drug appraisals and regulatory affairs.
- Actively engaged across the most popular social media applications, with around 10,000 interactions.
- We have gathered real stories via our engagement group and PAPAA surveys with more than 5,000 individual views and suggestions from lived-experience of psoriatic disease.
- Around three-quarters of a million pounds provided to support research and training initiatives in psoriatic disease.
- Regular updates provided via an eNewsletter to more than 1,300 people.
- Trained multidisciplinary healthcare professionals via our CPD accredited Psoriasis in Practice programme, with many subsidised to access the training at no cost.
- Provided anonymised access to peer-support to those often desperate for someone to listen and hear their voice.

Collaboration and involvement with other organisations and external agencies are seen by the charity as an important part of the advocacy and representation of the organisation's constituent group. This includes work with the Priority Setting Partnership with the James Lind Alliance, the British Association of Dermatologists, and The British Society for Rheumatology.

The charity joined the Connect Immune Research (CIR) initiative, which is a collective of type 1 diabetes charity JDRF, MS Society, and Versus Arthritis with support partner the British Society for Immunology. The intention is to learn how immune disorders are linked. To be more specific, 'what are the common mechanisms of autoimmunity and immune mediated inflammation?'. PAPAA believes that working collectively in collaboration is of benefit to those affected by psoriasis and psoriatic arthritis and associated conditions.

An ongoing process of data gathering and analysis of user issues, along with strategic distribution of electronic surveys and a standing open access PAPAA survey, have built a broad view of the needs of the constituent group the charity represents.

The use of this original generally unpublished data aided the submission of the patient's 'lived experience' to the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All-Wales Medicines Strategy Group (AWMSG) to drug appraisals for new medicines, has proven to be very valuable and provide a real-life perspective. Positive feedback was received following submissions, with the charity's approach being formally appreciated by the Patient and Public Engagement teams of the respective agencies.

Responding to calls from medicine agencies is seen as an important PAPAA representation role. This has also included proactive engagement by raising alarms and alerts to the Medicines Health Regulator Authority (MHRA), regarding misleading advertising, inappropriate promotion of psoriasis and psoriatic arthritis products, and where fake or adulterated medicine is being made available. This work is jointly from evaluation of the area of operation and through direct contact from people with the condition. This close engagement has also seen invitations to contribute to safety campaigns that provided a wider benefit beyond our area of work, by also providing a public benefit.

Supporting people to understand psoriasis and psoriatic arthritis and raise awareness to a wider audience had continued to be part of the work of the charity.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2021

Providing realistic support, that is backed by evidence and scientific rigour is key to that support. The role of meeting all those affected needs from cradle to grave also continues to be of the utmost importance.

A policy of open access to a confidential and anonymous helpline, has also been maintained. The support that is given generally follows a peer-to-peer approach of listening, showing empathy and then directional advice of how to get the most of the services provided within the NHS framework. This work, although, often intense and in depth, is often praised by service users as a useful and effective approach to supporting them in what can be a very difficult period, whether newly diagnosed or entering a different phase of life or disease stage. The ability to provide time, resource and signposting is also valued, with returning calls to seek further support often taking place.

Identification of areas that the charity can provide support and benefit in which it operates continues. Although during this financial year there was interruption and redeployment of healthcare professionals to deal and cope with the COVID-19, the organisation still received interest in its research provision, although some funds were distributed, there was considerable delay and no cost extension was given to grant holders.

The following continue to be the main areas of interest to the trustees:

- Short term observational studies
- Funding of feasibility and pilot studies
- Systematic reviews
- Small epidemiological surveys
- Psoriasis and psoriatic arthritis in children

PAPAA continues to hold partner status with the National Institute for Health Research (NIHR), which allows eligible research projects to be included in the NIHR Clinical Research Network Portfolio and therefore able to access NHS support via the NIHR Clinical Research Network infrastructure. Future support of relevant research will continue, but more focus and calls for appropriate aligned research may begin. This will change as the organisation's strategy direction is influenced by external demands.

Unmet needs

We have continued to engage with our constituent group particularly via our 'your views' and 'share your story' sections of our website. Regular surveys have allowed us to identify areas and themes that are important to patients. Analysis of website search terms and activity along with direct interaction with people has identified a number of topics where exploration is required. This work continues to influence the production of new content and support activities.

Public and patient engagement

This has become an important part of our work and aligns with growing expectation that charities need to demonstrate how their work is influenced by those they serve. PAPAA is continuing to engage with patients and the public in order to help our patient-centred approach to provide support based on need. We have an active user group that provides input and support.

PAPAA has also continued to engage at events, in order to represent the charity. These were exclusively online as virtual events, although there are some disadvantages to virtual engagement, the reduced resource implications to attend physical meetings and opportunity to attend more events, should be seen as an advantage of COVID-19 restrictions, but most importantly this wider attendance helps to raise issues that are relevant to people affected by psoriasis and psoriatic arthritis.

Apart from the forward planning ambitions of the charity, there still remains core day-to-day activities that continue to be carried out in support of people affected by psoriasis and psoriatic arthritis, these are as follows:

- Enquiries
- Website activity
- User interaction
- Fundraising
- Awareness and promotion
- Events/external involvement
- Social media post
- Horizon scanning
- Publications

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2021

Conclusion

Under the unprecedented circumstances that the pandemic brought, the charity and its staff have been able to meet the needs of those who use its services and were also able provide wider support and advice.

The previous risk assessment and decisions to upgrade the core websites, digital presentations, IT infrastructure and move towards cloud devices, allowed a quick deployment and reasonably seamless service, with limited disadvantages to those who engage. This demonstrated that the charity is well armed to meet any challenges it may face. Although the likely impact on income should not be underestimated, the interruptions in activity roll-out and delayed fundraising and awareness activity will hit PAPAA's ambitions and also the wider charity and voluntary sector, which will lead to more demand on limited resources and greater competition for funds.

Taking all of the issues that COVID-19 raised, going forward we intend to continue to expand our areas of work by continuing to develop a fundraising strategy to support and develop these key areas further, we will build and consolidate on the solid progress and implementation of the work identified and agreed by the trustees.

The global pandemic and subsequent wider social and political changes, will no doubt have a significant impact on health and social care services, charities are often seen as the service that will provide the support and answers to fulfil the gaps that will inevitably emerge, which will potentially be a very challenging process.

Financial review

The Trustees have decided to adopt a cautious approach to investment and have their funds spread in various secure cash bank and investment accounts. A managed ethical investment portfolio has been setup to maximize the funds not needed for immediate use. A review of the investment policy and returns is undertaken at Trustee meetings during the year.

Income generated for the year was £31,179 (2020: £52,922) and expenditure of £289,842 (2020: £322,052). The net deficit for the year was £84,426 (2020: £343,670).

Reserves policy

It is anticipated that expenditure will increase over the coming year and therefore the trustees consider unrestricted reserves of approximately £300,000 are required to cover one years operating costs. Currently designated funds are £1,086,600; these funds have been set aside by the trustees for investment to earn sufficient investment income to fund on-going research for Psoriasis and Psoriatic Arthritis.

Designated funds

The trustees have decided that a designated fund should be allocated to grants for research. The charity operates an open application small research grant programme, with a maximum award per application of £10,000.

The size of the fund allocation is £50,000 per financial year, which reflects the current and anticipated level of applications based on funded projects within the portfolio and that of rejected applications in the current financial year.

It is anticipated that the fund will be spent within each financial year, if not the funds will be carried forward to create a rolling offer, or used for support, which the trustees proactively identify as meeting with the aims and objectives of the charity. Awards will only be made based on extensive and thorough vetting of the applications.

Structure, governance and management

The Charity is a charitable company limited by guarantee and was incorporated on 30 January 2007. The company took over the assets, liabilities and activities of the Psoriasis Support Trust, an unincorporated charity, on 6 April 2007 and of the Psoriatic Arthropathy Alliance charitable company limited by guarantee on 3 April 2009 as agreed by the trustees of both charities.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

Paul Von Der Heyde (Chairman)

J. M. Peel

C. C. Auld

B. Lindsey

(Resigned 11 March 2021)

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2021

The charity is governed by a board of trustees who meet regularly. New trustees are recruited through other trustees. Before joining they are given a copy of the Memorandum & Articles of Association as well as accounts and they then meet with the trustees for induction and training.

The Trustees are satisfied that procedures are in place to identify and manage any significant risks to which the charity might be exposed.

None of the Trustees has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute no more than £10 in the event of winding up.

Public benefit
The sections of this report above entitled "Objectives and activities" and "Achievement and performance" set out the charity's objectives and reports on the activities and successes in the year to 5 April 2021 as well as explaining the plans for the current financial year.
The trustees have reviewed the public benefit criteria as set out by the Charities Commission in relation the charity's objects and believe the charity fulfils these as follows:
The charity serves a section of the general public who have specific issues with psoriasis and psoriatic arthritis. The charity's role here provides support and advice as a service free at access point. Wider awareness activities educate other members of the public to gain a better understanding of the disease and the nature of its course, particularly those who are affected either directly or indirectly by the condition as a relative, friend or employer.

The organisation operates an inclusive society policy and therefore provides support, advice and education to any member of the public who needs/requests it and ultimately receive subsequent benefit; this activity is free and requires no obligation or commitment from the individual(s) concerned. The trustees' believe this fulfils the charity's objectives, but also demonstrates the wider view of the general public as to what is deemed to be charitable.

Asset cover for funds

Note 19 and 20 sets out an analysis of the assets attributable to the various funds and a description of the trusts. These assets are sufficient to meet the charity's obligations on a fund by fund basis.

Auditor

A Resolution proposing that Xeinadin Audit Limited be reappointed as auditors of the company will be put to the members.

Disclosure of information to auditor

Each of the directors has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor are aware of such information.

The trustees' report was approved by the Board of Trustees.

Paul von der Heyde
.....

Paul Von Der Heyde (Chairman)

Trustee 04 Apr 2022

Dated:

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
STATEMENT OF TRUSTEES' RESPONSIBILITIES
FOR THE YEAR ENDED 5 APRIL 2021

The trustees, who are also the directors of Psoriasis and Psoriatic Arthritis Alliance for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE (A COMPANY LIMITED BY GUARANTEE)

INDEPENDENT AUDITOR'S REPORT

TO THE TRUSTEES OF PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE

Opinion

We have audited the financial statements of Psoriasis and Psoriatic Arthritis Alliance (the 'Charity') for the year ended 5 April 2021 which comprise the statement of financial activities, the balance sheet and the notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 5 April 2021 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the Charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

- the information given in the trustees' report, which includes the directors' report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the directors' report included within the trustees' report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the Charity and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report included within the trustees' report.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the trustees' report and from the requirement to prepare a strategic report.

Responsibilities of trustees

As explained more fully in the statement of trustees' responsibilities, the trustees, who are also the directors of the Charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the trustees are responsible for assessing the Charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

(Senior Statutory Auditor)

For and on behalf of Xeinadin Audit Limited

Chartered Accountants and Registered Auditors

Dalton House

9 Dalton Square

Lancaster

LA1 1WD

.....

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 5 APRIL 2021

		Unrestricted funds general 2021 £	Unrestricted funds designated 2021 £	Total 2021 £	Unrestricted funds general 2020 £	Unrestricted funds designated 2020 £	Total 2020 £
	Notes						
Income from:							
Donations and legacies	3	10,343	-	10,343	28,819	-	28,819
Investments	4	19,331	1,505	20,836	19,338	4,765	24,103
Total income		29,674	1,505	31,179	48,157	4,765	52,922
Expenditure on:							
Raising funds	5	9,587	-	9,587	9,362	-	9,362
Charitable activities							
Information and Support Services	6	280,255	-	280,255	312,690	-	312,690
Total charitable expenditure		280,255	-	280,255	312,690	-	312,690
Total resources expended		289,842	-	289,842	322,052	-	322,052
Net gains/(losses) on investments	11	174,237	-	174,237	(74,540)	-	(74,540)
Net outgoing resources before transfers		(85,931)	1,505	(84,426)	(348,435)	4,765	(343,670)
Gross transfers between funds		77,861	(77,861)	-	356,505	(356,505)	-
Net movement in funds		(8,070)	(76,356)	(84,426)	8,070	(351,740)	(343,670)
Fund balances at 6 April 2020		308,070	1,162,956	1,471,026	300,000	1,514,696	1,814,696
Fund balances at 5 April 2021		300,000	1,086,600	1,386,600	308,070	1,162,956	1,471,026

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
BALANCE SHEET

AS AT 5 APRIL 2021

	Notes	2021 £	£	2020 £	£
Fixed assets					
Intangible assets	12		52,859		75,840
Tangible assets	13		6,718		4,814
Investments	14		1,137,478		955,960
			<u>1,197,055</u>		<u>1,036,614</u>
Current assets					
Debtors	16	3,481		4,607	
Cash at bank and in hand		212,857		452,496	
		<u>216,338</u>		<u>457,103</u>	
Creditors: amounts falling due within one year	17	(26,793)		(22,691)	
		<u></u>		<u></u>	
Net current assets			189,545		434,412
Total assets less current liabilities			<u>1,386,600</u>		<u>1,471,026</u>
Income funds					
<u>Unrestricted funds</u>					
Designated funds	19	1,086,600		1,162,956	
General unrestricted funds		300,000		308,070	
		<u></u>		<u></u>	
			1,386,600		1,471,026
			<u>1,386,600</u>		<u>1,471,026</u>

04 Apr 2022

The financial statements were approved by the Trustees on

Paul von der Heyde

Paul Von Der Heyde (Chairman)

Trustee

Company Registration No. 06074887

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2021

1 Accounting policies

Charity information

The charity is a company limited by guarantee and has no share capital. The registered office is Acre House, 11-15 William Road, London, NW1 3ER. The liability of each member in the event of winding up is limited to £10.

1.1 Accounting convention

The accounts have been prepared in accordance with the Charity's governing document, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective from 1 January 2019). The Charity is a public benefit entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include certain financial instruments at fair value. The principal accounting policies adopted are set out below.

The accounts present information about the company as an individual undertaking and not about its group. The company and its subsidiary undertaking comprise a small-sized group. The company has therefore taken advantage of the exemptions provided by section 398 of the Companies Act 2006 not to prepare group accounts.

1.2 Going concern

The trustees have considered the effect of the prolonged Covid-19 outbreak. The trustees consider that the outbreak is unlikely to cause significant disruption to the charity's activities and are confident that the charity can continue as a going concern for a period of at least 12 months from the date of approval of these financial statements. The trustees have a reasonable expectation that the charity has adequate resources to continue in operation for the foreseeable future.

1.3 Charitable funds

Funds held by the charity are:

Unrestricted general funds - these are the funds which can be used in accordance with the charitable objects at the discretion of the trustees.

Designated funds - these are the funds set aside by the trustees out of unrestricted general funds for specific future purposes or projects.

Further explanation of the nature and purpose of each fund is included in the notes to the accounts.

1.4 Incoming resources

Income is recognised when the Charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the Charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the Charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Grants are recognised in full in the Statement of Financial Activities in the year in which they are receivable or any requirement imposed on the grant is fulfilled.

Interest on funds held on deposit is included upon notification of the interest paid or payable by the bank. Dividends are recognised once the dividend has been declared and notification has been received by our investment advisor of the investment portfolio.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2021

1 Accounting policies

(Continued)

1.5 Resources expended

Liabilities are recognised as expenditure once there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses, including support costs and governance costs, are allocated to the charitable activity in the statement of financial activities.

Grants payable are charged in the period in which the grant is approved by the trustees except where the offer is conditional, in which case they are recognised when the attached conditions are fulfilled. Grants subject to conditions which have not been met at the year end are noted as commitment but not accrued as expenditure.

Governance costs included those costs incurred in the governance of the charity's assets and are primarily associated with constitutional and statutory requirements.

Irrecoverable VAT is charged against the expenditure heading for which it was incurred.

1.6 Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Website cost	20% reducing balance
--------------	----------------------

Current year amortisation expense includes amortisation for period from 09 September 2019 to 30 April 2021.

1.7 Tangible fixed assets

Tangible fixed assets are measured at cost net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Plant and machinery	25% reducing balance
Fixtures, fittings & equipment	25% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2021

1 Accounting policies

(Continued)

1.8 Fixed asset investments

Fixed asset investments consists of listed investments and shares in a subsidiary undertaking.

Listed investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

The investment includes the charity's holding in its subsidiary trading company and is shown at cost.

A subsidiary is an entity controlled by the Charity. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand and deposits held at call with banks.

1.10 Financial instruments

The Charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

1.11 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the Charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12 Retirement benefits

The Charity operates a defined contributions pension scheme. Contributions are charged in the accounts as they become payable in accordance with the rules of the scheme.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2021

2 Critical accounting estimates and judgements

In the application of the Charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The Trustees do not consider there to be judgements or estimates that would be considered to be critical to the financial statements.

3 Donations and legacies

	2021	2020
	£	£
Donations	10,343	10,362
Legacies received	-	18,457
	<u>10,343</u>	<u>28,819</u>

All donations and subscriptions in 2021 and 2020 were unrestricted.

4 Investments

	Unrestricted funds general 2021 £	Unrestricted funds designated 2021 £	Total 2021 £	Unrestricted funds general 2020 £	Unrestricted funds designated 2020 £	Total 2020 £
Income from listed investments	16,868	-	16,868	18,288	-	18,288
Interest receivable	2,463	1,505	3,968	1,050	4,765	5,815
	<u>19,331</u>	<u>1,505</u>	<u>20,836</u>	<u>19,338</u>	<u>4,765</u>	<u>24,103</u>

5 Raising funds

	Unrestricted 2021 £	Unrestricted 2020 £
<u>Investment management</u>	9,587	9,362
	<u>9,587</u>	<u>9,362</u>

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2021

6 Charitable activities

	Information and Support Services 2021 £	Information and Support Services 2020 £
Medical consultancy	20,303	26,021
Printing and stationery	6,231	24,868
Contribution to PAPAA Enterprises Limited	338	695
	<u>26,872</u>	<u>51,584</u>
Grant funding of activities (see note 7)	8,500	49,496
Share of support costs (see note 8)	217,279	194,621
Share of governance costs (see note 8)	27,604	16,989
	<u>280,255</u>	<u>312,690</u>

Net expenditure in the year is stated after charging audit fees of £2,900 (2020: £NIL), depreciation of owned tangible fixed assets of £2,127 (2020: £900).

All expenditure on charitable activities in 2021 and 2020 was unrestricted.

7 Grants payable

	Information and Support Services 2021 £	Information and Support Services 2020 £
Grants to institutions:		
Queen's University Belfast	-	32,175
Dermnet NZ	-	17,321
The University of Liverpool	8,500	-
	<u>8,500</u>	<u>49,496</u>

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2021

8 Support costs

	Support costs	Governance costs	2021	2020
	£	£	£	£
Staff costs	146,257	-	146,257	146,077
Depreciation	25,108	-	25,108	900
Rent and rates	24,010	-	24,010	24,578
IT consultancy	12,359	-	12,359	2,600
Postage	4,563	-	4,563	10,721
Telephone and fax	2,352	-	2,352	2,153
Other expenses	926	-	926	4,932
Subscriptions	504	-	504	873
Travel	-	-	-	387
Training cost	1,200	-	1,200	1,400
Audit fees	-	2,900	2,900	-
Legal and professional	-	23,419	23,419	16,426
Insurance	-	1,285	1,285	563
	<u>217,279</u>	<u>27,604</u>	<u>244,883</u>	<u>211,610</u>
Analysed between				
Charitable activities	<u>217,279</u>	<u>27,604</u>	<u>244,883</u>	<u>211,610</u>

9 Trustees

None of the trustees (or any persons connected with them) received any remuneration during the year or reimbursed expenses.

10 Employees

Number of employees

The average monthly number of employees during the year was:

	2021 Number	2020 Number
Administration	<u>3</u>	<u>3</u>
Employment costs	2021	2020
	£	£
Wages and salaries	131,250	129,320
Social security costs	10,476	11,274
Other pension costs	4,531	5,483
	<u>146,257</u>	<u>146,077</u>

There were no employees whose annual remuneration was £60,000 or more (2020: nil).

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2021

11 Net gains/(losses) on investments

	Unrestricted funds general 2021 £	Unrestricted funds general 2020 £
Revaluation of investments	161,111	(74,540)
Gain/(loss) on sale of investments	13,126	-
	<u>174,237</u>	<u>(74,540)</u>

12 Intangible fixed assets

	Website cost £
Cost	
At 6 April 2020 and 5 April 2021	75,840
Amortisation and impairment	
At 6 April 2020	-
Amortisation charged for the year	22,981
At 5 April 2021	22,981
Carrying amount	
At 05 April 2021	52,859
At 05 April 2020	75,840

Amortisation charge includes £13,215 for current year and £9,766 for 2020.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2021

13 Tangible fixed assets

	Plant and machinery £	Fixtures, fittings & equipment £	Total £
Cost			
At 6 April 2020	3,543	10,521	14,064
Additions	-	4,031	4,031
At 5 April 2021	3,543	14,552	18,095
Depreciation and impairment			
At 6 April 2020	3,394	5,856	9,250
Depreciation charged in the year	37	2,090	2,127
At 5 April 2021	3,431	7,946	11,377
Carrying amount			
At 5 April 2021	112	6,606	6,718
At 5 April 2020	149	4,665	4,814

14 Fixed asset investments

	Listed investments £	Cash in portfolio	Investment in subsidiary	Total £
Cost or valuation				
At 6 April 2020	941,155	14,804	1	955,960
Additions	49,538	(49,538)	-	-
Valuation changes	161,111	-	-	161,111
Dividend and interest income	-	16,868	-	16,868
Management fees	-	(9,587)	-	(9,587)
Disposals	(49,672)	62,798	-	13,126
At 5 April 2021	1,102,132	35,345	1	1,137,478
Carrying amount				
At 05 April 2021	1,102,132	35,345	1	1,137,478
At 05 April 2020	941,155	14,804	1	955,960

	Notes	2021 £	2020 £
Other investments comprise:			
Investment in subsidiary	22	1	1

Information on the subsidiary undertaking is disclosed in note 24 of the accounts.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 5 APRIL 2021

15	Financial instruments	2021	2020
		£	£
	Carrying amount of financial assets		
	Instruments measured at fair value through profit or loss	1,102,132	941,155
16	Debtors	2021	2020
		£	£
	Amounts falling due within one year:		
	Other debtors	2,600	2,687
	Prepayments and accrued income	881	1,920
		3,481	4,607
17	Creditors: amounts falling due within one year	2021	2020
		£	£
	Other taxation and social security	4,457	4,430
	Trade creditors	3,733	12,376
	Amounts owed to subsidiary undertakings	1	1
	Accruals and deferred income	18,602	5,884
		26,793	22,691

18 Retirement benefit schemes

The Charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the Charity in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £3,272 (2020: £5,483).

19 Designated funds

The income funds of the charity include the following designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes:

	Movement in funds		
	Balance at 6 April 2020	Incoming resources	Balance at 5 April 2021
	£	£	£
Investment and research fund	1,115,956	1,505	1,039,600
Small research grant programme	47,000	-	47,000
	1,162,956	1,505	1,086,600

The investment and research fund represent sums set aside by the trustees for investments. To earn sufficient income to fund on going research in Psoriasis and Psoriatic Arthritis.

PSORIASIS AND PSORIATIC ARTHRITIS ALLIANCE
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 5 APRIL 2021

19 Designated funds

(Continued)

The trustees have decided that a designated fund should be allocated to grants for research. The charity operates an open application small research grant programme, with a maximum award per application of £10,000. The size of the fund allocation (£47,000) reflects the current and anticipated level of applications based on funded projects within the portfolio and that of rejected applications in the current financial year. It is anticipated that the fund will be spent within each financial year, but awards will only be made based on extensive and thorough vetting of the applications, unused funds will be carried over or used for support, which the trustees proactively identify as meeting with the aims and objectives of the charity.

20 Analysis of net assets between funds

	Unrestricted funds	Designated funds	Total	Unrestricted funds	Designated funds	Total
	2021	2021	2021	2020	2020	2020
	£	£	£	£	£	£
Fund balances at 5 April 2021 are represented by:						
Intangible fixed assets	52,859	-	52,859	75,840	-	75,840
Tangible assets	6,718	-	6,718	4,814	-	4,814
Investments	1,137,478	-	1,137,478	955,960	-	955,960
Current assets/(liabilities)	(897,055)	1,086,600	189,545	(728,544)	1,162,956	434,412
	<u>300,000</u>	<u>1,086,600</u>	<u>1,386,600</u>	<u>308,070</u>	<u>1,162,956</u>	<u>1,471,026</u>

21 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

	2021 £	2020 £
Aggregate compensation	<u>57,679</u>	<u>56,837</u>

Psoriasis and Psoriatic Arthritis Alliance has licensed the use of eTips website to PAPAA Enterprises Limited a wholly owned subsidiary. This activity is within the objects of the charity and therefore considered to be primary purpose trading. At the end of the year Psoriasis and Psoriatic Arthritis Alliance owed £1 (2020: £1) to PAPAA Enterprises Limited and contributed £398 (2020: £695) towards the website.

22 Subsidiaries

Details of the Charity's subsidiaries at 5 April 2021 are as follows:

Name of undertaking	Registered office	Nature of business	Class of shares held	% Held Direct Indirect
PAPAA Enterprises Limited	Acre House, 11-15 William Road, London, NW1 3ER, United Kingdom	Website Licence	Ordinary	100.00



Issuer HW Fisher

Document generated Tue, 5th Apr 2022 10:42:45 BST

Document fingerprint aff97c0ad8800edc1c40024d032b87b5

Parties involved with this document

Document processed	Party + Fingerprint
Tue, 5th Apr 2022 15:22:12 BST	Paul von der Heyde - Signer (9f4a0b258ac0f3195b3c4ffe6492646d)
Tue, 5th Apr 2022 15:22:12 BST	Laurence Holman - Copied In (c554f27dc8269f1d25848043cca9b06d)

Audit history log

Date	Action
Tue, 5th Apr 2022 15:22:14 BST	Document emailed to LHolman@hwfisher.co.uk (18.135.28.38)
Tue, 5th Apr 2022 15:22:12 BST	The envelope has been signed by all parties. (86.140.23.171)
Tue, 5th Apr 2022 15:22:12 BST	Sent a copy of the envelope to Laurence Holman (LHolman@hwfisher.co.uk). (86.140.23.171)
Tue, 5th Apr 2022 15:22:12 BST	Paul von der Heyde signed the envelope. (86.140.23.171)
Tue, 5th Apr 2022 15:19:37 BST	Paul von der Heyde viewed the envelope. (86.140.23.171)
Tue, 5th Apr 2022 15:19:02 BST	Paul von der Heyde opened the document email. (86.140.23.171)
Tue, 5th Apr 2022 15:19:02 BST	Paul von der Heyde opened the document email. (86.140.23.171)
Tue, 5th Apr 2022 12:30:29 BST	Paul von der Heyde viewed the envelope. (185.99.79.44)
Tue, 5th Apr 2022 12:30:22 BST	Paul von der Heyde opened the document email. (104.28.86.113)
Tue, 5th Apr 2022 12:02:11 BST	Paul von der Heyde opened the document email. (172.226.0.95)
Tue, 5th Apr 2022 10:51:08 BST	Paul von der Heyde opened the document email. (66.249.92.219)
Tue, 5th Apr 2022 10:50:42 BST	Document emailed to paulv.derh@gmail.com (3.8.198.33)
Tue, 5th Apr 2022 10:50:41 BST	Sent the envelope to Paul von der Heyde (paulv.derh@gmail.com) for signing. (217.207.100.70)
Tue, 5th Apr 2022 10:44:57 BST	Laurence Holman has been assigned to this envelope (217.207.100.70)
Tue, 5th Apr 2022 10:44:57 BST	Paul von der Heyde has been assigned to this envelope (217.207.100.70)
Tue, 5th Apr 2022 10:43:01 BST	Document generated with fingerprint 5e2d84eb6cf54ca6226db53518ab8a81 (217.207.100.70)
Tue, 5th Apr 2022 10:43:00 BST	Document generated with fingerprint 4772852956ab286e28c1b283166da0d9 (217.207.100.70)

Tue, 5th Apr 2022 10:42:56 BST	Document generated with fingerprint e86b501f9c2849f69de6106a83f99ab3 (217.207.100.70)
Tue, 5th Apr 2022 10:42:54 BST	Document generated with fingerprint 2603ab811a318db763601608ae0ff62c (217.207.100.70)
Tue, 5th Apr 2022 10:42:50 BST	Document generated with fingerprint aff97c0ad8800edc1c40024d032b87b5 (217.207.100.70)
Tue, 5th Apr 2022 10:42:45 BST	Envelope generated by Shafayat Khan (217.207.100.70)